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ANALYZING SURVIVAL DATA FOR SEQUENTIALLY RANDOMIZED
DESIGNS
Xinyu Tang, PhD
University of Pittsburgh, 2010
Sequentially randomized designs are becoming common in biomedical research, particularly
in clinical trials. These trials are usually designed to evaluate and compare the effect of
different treatment regimes. In such designs, eligible patients are first randomly assigned
to receive one of the initial treatments. Patients meeting some criteria (e.g. no progressive
diseases) are then randomized to receive one of the maintenance treatments. Usually, the
procedure continues until all treatment options are exhausted. Such multistage treatment
assignment results in dynamic treatment regimes consisting of initial treatment, intermediate
response and second stage treatment. However, methods for efficient analysis of sequentially
randomized trials have only been developed very recently. As a result, earlier clinical trials
reported results based only on the comparison of stage-specific treatments.
We first propose to use accelerated failure time and proportional hazards models for
estimating the effects of treatment regimes from sequentially randomized designs. Based on
the proposed models, differences between treatment regimes in terms of their hazards are
tested. We investigate the properties of these methods and tests in a Monte Carlo simulation
study. Finally the proposed models are applied to the long-term outcome of the high risk
neuroblastoma study.
We then extend the proportional hazards model to a generalized Cox proportional haz-
ards model that applies to comparisons of any combination of any number of treatment
regimes regardless of the number of stages of treatment. Contrasts of dynamic treatment
regimes are tested using the Wald chi-square method. Both the model and Wald chi-square
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tests of contrasts are illustrated through a simulation study and an application to a high
risk neuroblastoma study to complement the earlier results reported on this study.
Chronic diseases such as cancer and cardiovascular diseases are major causes of mortality
and morbidity in the United States and in the world. Sequentially randomized designs are
commonly used in clinical studies investigating treatments of chronic diseases such as cancer,
AIDS, and depression. The public health significance of the methodologies proposed in this
research is to allow efficient analysis of data from such studies and thereby enhance the
discovery of efficient maintenance and eradication strategies for chronic diseases.
Keywords: Accelerated failure time model, Cox proportional hazards model, Dynamic
treatment regime, High risk neuroblastoma study, Proportional hazards model, Sequen-
tially randomized design, Time-dependent covariates.
v
TABLE OF CONTENTS
PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
1.0 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 Sequentially randomized designs . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Dynamic treatment regimes . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 High risk neuroblastoma study . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.4 Motivation and organization . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.0 ACCELERATED FAILURE TIME AND PROPORTIONAL
HAZARDS MODELS FOR SEQUENTIALLY RANDOMIZED DE-
SIGNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2 Notation and Assumptions . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.3.1 Nonparametric Methods . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.3.2 Semiparametric Methods . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.3.3 Parametric Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.3.4 Treatment Regime Comparisons . . . . . . . . . . . . . . . . . . . . . 15
2.4 Simulation Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.5 Analysis of Neuroblastoma Dataset . . . . . . . . . . . . . . . . . . . . . . . 22
3.0 COX PROPORTIONAL HAZARDS MODEL FOR COMPARING
DYNAMIC TREATMENT REGIMES WITH TIME DEPENDENT
INTERMEDIATE RESPONSE . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
vi
3.2 Notation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.3 The Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.4 Simulation Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.5 Analysis of Neuroblastoma Dataset . . . . . . . . . . . . . . . . . . . . . . . 41
4.0 CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
BIBLIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
vii
LIST OF TABLES
1 Simulation scenarios . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2 Survival estimates (EST), standard errors (SE) in parentheses, and coverage
probability of 95% confidence interval (CP) at t = 1 year . . . . . . . . . . . 19
3 Survival estimates (EST), standard errors (SE) in parentheses, and coverage
probability of 95% confidence interval (CP) at t = 3 year . . . . . . . . . . . 20
4 The rejection rates of Fleming-Harrington tests . . . . . . . . . . . . . . . . . 21
5 AIC values for a total of 18 models fitted to the neuroblastoma dataset . . . 23
6 Fleming-Harrington test results for the neuroblastoma dataset . . . . . . . . 28
7 Data from four hypothetical patients in a two-stage randomization design. . . 32
8 Simulation results under scenario I . . . . . . . . . . . . . . . . . . . . . . . . 38
9 Simulation results under scenario II . . . . . . . . . . . . . . . . . . . . . . . 39
10 Simulation results under scenario III . . . . . . . . . . . . . . . . . . . . . . . 40
11 Wald chi-square test results under scenarios I, II and III . . . . . . . . . . . . 42
12 Wald chi-square test results for the neuroblastoma dataset . . . . . . . . . . . 44
viii
LIST OF FIGURES
1 A conceptual framework of a two-stage randomization design. . . . . . . . . . 2
2 Overall survival curves under four treatment regimes in the neuroblastoma
study based on NA estimator, PHM and AFTM . . . . . . . . . . . . . . . . 25
3 Comparisons of three methods for four treatment regimes in the neuroblastoma
study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4 Overall survival curves under four treatment regimes in the neuroblastoma
study based on WRSE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
ix
PREFACE
This dissertation is about the estimation of the survival quantities (e.g. hazards, survival
probabilities) under various regimes and effective contrasts of different regimes in sequentially
randomized clinical trials. I have been very fortunate to be surrounded by people, who helped
me a lot throughout my dissertation research.
First of all, I would like to express my sincere gratitude to my advisor, Dr. Abdus S.
Wahed, who contributed his ideas and comments on various theoretical and textual issues
to the quality of this dissertation. It was also him, who first exposed me to the statistical
topic about sequentially randomized designs. With my interest in this topic blooming, we
achieved the accomplishment showed in this dissertation. Because of his confidence in me, I
blundered through the tough part of my research.
I was also much beholden to my dissertation committee members, Dr. Howard E. Rock-
ette, Dr. Joseph P. Costantino, and Dr. Joyce Ho Chang, for their insightful opinions and
timely feedbacks.
Heartily gratefulness should also be given to my classmates and friends in Pittsburgh.
They helped me get used to the study and life in Pittsburgh, and we shared a lot of happy
moments together, which I would cherish for my whole life.
Finally, I would like to thank my husband, my parents and my parents-in-law for their
selfless support and encouragement in my life as well as in my research. Without them, I
would not be able to become a confident and grateful person I am now. Last but not the
least, I want to say that my daughter, Claire, is the most precious gift I had during my PhD
life. I also want to thank her for making me a proud mother.
x
1.0 INTRODUCTION
In this chapter, we describe important concepts that will be used frequently throughout the
dissertation. We also describe the study that motivated this research. Finally, we provide a
motivation and background for the research presented in subsequent chapters.
1.1 SEQUENTIALLY RANDOMIZED DESIGNS
Sequentially randomized designs are becoming common in biomedical research, particularly
in clinical trials. These trials are usually designed to assess and compare the effects of differ-
ent treatment regimes resulting from medical decision making at different stages of therapy.
In a sequentially randomized clinical trial, eligible patients are first randomly assigned to
receive one of the initial treatments. Patients meeting some criteria (e.g. no progressive
diseases) are then randomized to receive one of the maintenance treatments. Usually, the
procedure continues until all treatment options are exhausted. The basic structure of a two-
stage randomization design is depicted in Figure 1. In this two-stage randomization design,
patients are randomly assigned to J initial treatments, namely, A1, A2, ..., AJ−1, AJ . Then
patients with a response (e.g. without progressive diseases) are re-randomized to K mainte-
nance treatments, namely, B1, B2, ..., BK−1, BK , upon consent to further randomization.
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Figure 1: A conceptual framework of a two-stage randomization design.
1.2 DYNAMIC TREATMENT REGIMES
Dynamic treatment regimes are algorithms for assigning treatments to patients with complex
diseases, where treatment consists of more than one episode of therapy, potentially with
different dosages of the same agent or different agents. The multistage treatment assignment
in sequentially randomized clinical trials results in dynamic treatment regimes consisting of
initial treatment, intermediate response, and second stage treatment. A dynamic treatment
regime in a two-stage treatment setting consists of an initial treatment, a decision rule
for choosing the second-stage treatment, and the second-stage treatment. For example,
in the setting described in Figure 1, a treatment regime could be “Treat with Aj (initial
treatment), if patients respond and consent to further randomization, treat with Bk (second-
stage treatment)”. This is a dynamic treatment regime since the assignment of second-stage
treatments depends on the intermediate outcome (response). We will denote the above
regime by AjBk.
2
1.3 HIGH RISK NEUROBLASTOMA STUDY
Between 1991 and 1996, the Children’s Cancer Group commenced a high risk neuroblastoma
study aiming to assess whether a combination of myeloablative chemotherapy, total-body ir-
radiation, and transplantation of autologous bone marrow purged of cancer cells (ABMT)
improves event-free survival in children with high-risk neuroblastoma compared to inten-
sive non-myeloablative chemotherapy, and to determine whether subsequent treatment with
13-cis-rectinoic acid (cis-RA) improves event-free survival further compared to no further
therapy [13]. A two-stage randomization design was used for the treatment assignment. All
patients were first treated with induction chemotherapy. Then 379 eligible patients without
progressive diseases participated in the first-stage randomization, with 190 patients assigned
to chemotherapy and 189 patients assigned to ABMT. A total of 176 patients either had
progressive diseases or declined further randomization, so only 203 patients participated in
the second stage randomization, with 102 patients assigned to cis-RA and 101 patients as-
signed to no further therapy. Thus, four possible treatment regimes could be constructed
under the neuroblastoma study: (i) treat with chemotherapy followed by cis-RA if no pro-
gressive diseases present (CCR); (ii) treat with chemotherapy followed by no further therapy
if no progressive diseases (CNR) present; (iii) treat with ABMT followed by cis-RA if no
progressive diseases (ACR) present; (iv) treat with ABMT followed by no further therapy if
no progressive diseases present (ANR). This formulation of dynamic treatment regimes from
multistage treatment assignment allows simultaneous assessment of both first and second
stage treatments, which has been the focus of such clinical trials.
1.4 MOTIVATION AND ORGANIZATION
Initial results from the outcome of the study was reported in Matthay et al. [13]. Us-
ing Kaplan-Meier procedure, probabilities of event-free survival beyond three years were
estimated for both initial treatments ABMT and chemotherapy. A test of the signifi-
cance of the differences in event-free survival at 3 years confirmed the superiority of ABMT
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over chemotherapy alone. The study also compared cis-RA with no further therapy after
chemotherapy or transplantation in improving the event-free survival among children with
high-risk neuroblastoma. The difference in the event-free survival was statistically signifi-
cant in favor of cis-RA therapy. In a follow up to their original publication, Matthay et al.
[12] showed that ABMT significantly improves 5-year event-free survival and overall survival
compared to non-myeloablative chemotherapy, and cis-RA provided after chemotherapy or
transplantation significantly improves overall survival compared to no further therapy after
consolidation.
However, the statistical analyses reported in these articles were not efficient and may
have been inappropriate as well, since they did not take into account the information of
those patients who had progressive disease or histologically confirmed disease before the
second stage of treatment. Besides, the analyses only compared ABMT to chemotherapy
alone ignoring subsequent randomization to cis-RA or no further therapy and compared cis-
RA to no further therapy only among those who did not have progressive or histologically
confirmed disease. Separate analyses for the first stage and second stage treatments may not
be valid as they ignore the prior or post therapies received and the analysis is conditional
on patients becoming eligible to receive second stage treatment [11].
There has been significant development in statistical methods for analyzing sequentially
randomized designs (details are given in Sections 2.1 and 3.1). However, all the methods only
apply to the comparisons of treatment regimes that share the same second stage therapy. In
Chapter 2, We first propose to use accelerated failure time and proportional hazards models
for estimating the effects of treatment regimes from sequentially randomized designs. Based
on the proposed models, differences between treatment regimes in terms of their hazards
are also tested. We investigate the properties of these methods and tests in a Monte Carlo
simulation study. Finally the proposed models are applied to the long-term outcome of the
high risk neuroblastoma study.
In Chapter 3, which is a follow-up study to the work presented in Chapter 2, we extend the
proportional hazards model to a generalized Cox proportional hazards model that applies
to comparisons of any combination of any number of treatment regimes regardless of the
number of stages of treatment. Contrasts of dynamic treatment regimes are tested using
4
the Wald chi-square method. Both estimates and Wald chi-square tests of contrasts are
evaluated through a simulation study. An application to a high risk neuroblastoma study
complemented the earlier results reported on this study.
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2.0 ACCELERATED FAILURE TIME AND PROPORTIONAL
HAZARDS MODELS FOR SEQUENTIALLY RANDOMIZED DESIGNS
2.1 INTRODUCTION
The last decade has seen considerable advancement in the development of statistical meth-
ods for estimating the effects of dynamic treatment regimes [17, 15, 16, 11, 23, 24, 6, 5, 10].
Murphy et al. [17] developed marginal models for the mean response for a given dynamic
treatment regime. In a follow-up article [15] they provided a methodology for constructing
the optimal dynamic treatment regime. Lunceford et al. [11] proposed consistent survival
and mean restricted survival estimators for treatment regimes in a two-stage randomization
design. Wahed and Tsiatis [23, 24] introduced the most efficient estimator utilizing addi-
tional information from auxiliary variables. Guo and Tsiatis [5] derived a weighted risk set
estimator (WRSE) on the basis of counting process theory [4] using a time-varying mea-
surement for the intermediate response. Hernan et al. [6] described a simple method to
compare dynamic treatment regimes via inverse probability weighting. Murphy and Bing-
ham [16] used screening experiments to identify potential treatment components and screen
out insignificant ones for developing dynamic treatment regimes.
Other articles focused on the comparisons of dynamic treatment regimes from two-stage
randomization designs [10, 3]. Lokhnygina and Helterbrand [10] extended the Cox regres-
sion method to the estimation of log hazards of dynamic treatment regimes in a two-stage
randomization design and applied a robust score test to compare two treatment regimes
sharing the same second-stage treatment. Feng and Wahed [3] presented a modified supre-
mum weighted log-rank test to test the equality of two dynamic treatment regimes. Both
tests applied only to the comparisons of treatment regimes that share the same second-stage
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therapy. In this article, we used accelerated failure time and proportional hazards models
to derive the survival estimators for dynamic treatment regimes. Based on the proposed
models, we also tested the equality of two survival distributions for any pairs of treatment
regimes.
This chapter is organized as follows. In Section 2.2, we introduce the notation and
assumptions. In Section 2.3, we describe the methods proposed for estimating the survival
quantities and for comparing different treatment regimes based on the overall survival. In
Section 2.4, a Monte Carlo simulation study is carried out to examine the performance of
the proposed models. In Section 2.5, we analyze the high risk neuroblastoma dataset to
compare overall survival for different neuroblastoma treatment regimes.
2.2 NOTATION AND ASSUMPTIONS
The basic structure of a two-stage randomization design is depicted in Figure 1, which
reflects the design of the high risk neuroblastoma study described in brief in Section 2.1
(details are given in Section 2.5). In this two-stage randomization design, patients are
randomly assigned to J initial treatments, namely, A1, A2, ..., AJ−1, AJ . Then patients
with a response (e.g. without progressive diseases) are re-randomized to K maintenance
treatments, namely, B1, B2, ..., BK−1, BK , upon consent to further randomization. A
dynamic treatment regime in a two-stage treatment setting consists of an initial treatment,
a decision rule for choosing the second-stage treatment, and the second-stage treatment.
For example, in the setting described in Figure 1, a treatment regime could be “Treat with
Aj (initial treatment), if patients respond and consent to further randomization, treat with
Bk (second-stage treatment)”. This is a dynamic treatment regime since the assignment of
second-stage treatments depends on the intermediate outcome (response). We will denote
the above regime by AjBk. The goal is to estimate survival quantities (e.g. hazards, survival
probabilities) under various regimes and compare their effects. To facilitate this we resort to
the idea of counterfactual variables from the causal inference literature. Although we are not
particularly interested in the causal inference, this formulation will help us develop methods
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to serve our goal.
Assume that the ith individual has a set of potential outcomes or counterfactuals [7]
{
R∗ji, T
∗
j0i, T
∗
jki, j = 1, ..., J, k = 1, ..., K
}
,
where R∗ji is the potential intermediate response for the ith patient were he/she assigned
Aj as the initial treatment; T
∗
j0i is the potential survival time for the ith patient if he/she
were on Aj as the initial therapy, and did not respond; and T
∗
jki indicates the potential
survival time for the ith patient if he/she were on Aj as the initial therapy, responded and
was consequently assigned Bk as the maintenance therapy. Then by definition, the overall
survival for the ith patient under treatment regime AjBk can be written as
Tjki = (1−R∗ji)T ∗j0i +R∗jiT ∗jki.
In terms of these survival quantities, we define the hazard
λAjBk(t) = lim
∆t→ 0
P (t < Tjk < t+ ∆t)
P (Tjk > t)∆t
,
and the corresponding survival function SAjBk(t) = P (Tjk > t). Note that for a given
individual i, not all JK survival times Tjki, j = 1, ..., J, k = 1, ..., K can be observed, since in
practice, a patient i cannot receive all treatment sequences. In fact, the observed data from
a two-stage randomization design can be expressed as
{Xji, Ri, RiZki, Ui,∆i},
where
Xji is the indicator for jth initial treatment, Xji = 1 if the ith patient was assigned to
Aj as initial treatment, and Xji = 0 if otherwise;
Ri is the indicator for response and consent, Ri = 1 if the ith patient responded to the
initial treatment and consent to further randomization, and Ri = 0 if otherwise;
Zki = 1 if the ith patient was assigned to Bk as maintenance treatment, and Zki = 0 if
otherwise (note that Zki is defined only when Ri = 1);
and Ui denotes the observed death (∆i = 1) or censoring time (∆i = 0). In other words,
when ∆i = 1, Ui = Ti, the potential survival time, and when ∆i = 0, Ui = Ci, the potential
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censoring time. We assume that censoring is independent of observed data and counterfac-
tuals. Patients who were censored without a response were treated as nonresponders (since
a response was not observed before being censored; see Lunceford et al. [11]).
In order to draw inferences on counterfactual variables Tjk, j = 1, ..., J, k = 1, ..., K,
one needs to make certain assumptions about the relationship between counterfactual and
observed data. The first assumption is the consistency assumption [1], which could be
described in statistical terms as
Ri =
J∑
j=1
XjiR
∗
ji,
and
Ti =
J∑
j=1
{
Xji
[
(1−R∗ji)T ∗j0i +R∗ji
(
K∑
k=1
ZkiT
∗
jki
)]}
. (2.1)
In words, in the absence of censoring, the observed response and survival time for the ith
patient equal his/her potential response and survival time under his/her observed treat-
ment assignments. For example, if the ith patient was assigned to A3 as initial treat-
ment, responded and was consequently assigned to B5 as maintenance treatment, then
the observed survival time for the ith patient is equal to the potential survival time un-
der treatment regime A3B5, namely, Ti = T35i = T
∗
35i. The other assumption is the
“No unmeasured confounder” assumption. Briefly, patients with various treatment as-
signments have the equal distribution of potential outcomes [1]. This assumption can be
expressed statistically as P (Xj = 1|Tjk, j = 1, ..., J, k = 1, ..., K) = P (Xj = 1), and
P (Zk = 1|R = 1, Tjk, j = 1, ..., J, k = 1, ..., K) = P (Zk = 1|R = 1). Denote piZk to be
the probability of a patient being assigned to maintenance treatment Bk given that the
patient responded to the initial treatment, namely, piZk = P (Zk = 1|R = 1). In further
developments, this will be assumed known, since the assignment is done through random-
ization.
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2.3 METHODS
Our goal is to find the survival and hazard estimators for the treatment regimes AjBk, and
also provide contrasts for comparing regimes AjBk, j = 1, ..., J and k = 1, ..., K based on the
overall survival. Define λjk(t) and Sjk(t) to be the hazard and survival functions respectively
corresponding to the counterfactual variable T ∗jk, j = 1, ..., J ; k = 0, 1, ...K, then the hazard
function λAjBk(t) of the treatment regime AjBk can be expressed in terms of λjk(t) and
Sjk(t), j = 1, ..., J ; k = 0, 1, ..., K as follows:
λAjBk(t) = lim
∆t→ 0
P (t < Tjk < t+ ∆t)
P (Tjk > t) ∆t
= lim
∆t→ 0
P
(
t < T ∗jk < t+ ∆t|R = 1
)
P (R = 1) + P
(
t < T ∗j0 < t+ ∆t|R = 0
)
P (R = 0)[
P
(
T ∗jk > t|R = 1
)
P (R = 1) + P
(
T ∗j0 > t|R = 0
)
P (R = 0)
]
∆t
= lim
∆t→ 0
P
(
t < T ∗jk < t+ ∆t
)
pij + P
(
t < T ∗j0 < t+ ∆t
)
(1− pij)[
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
]
∆t
=
P
(
T ∗jk > t
)
P
(
T ∗j0 > t
)
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
lim
∆t→ 0
P
(
t < T ∗jk < t+ ∆t
)
P
(
T ∗jk > t
)
∆t
pij
P
(
T ∗j0 > t
) + P (t < T ∗j0 < t+ ∆t)
P
(
T ∗j0 > t
)
∆t
1− pij
P
(
T ∗jk > t
)

=
P
(
T ∗jk > t
)
pij
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
lim
∆t→ 0
P
(
t < T ∗jk < t+ ∆t
)
P
(
T ∗jk > t
)
∆t
+
P
(
T ∗j0 > t
)
(1− pij)
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
lim
∆t→ 0
P
(
t < T ∗j0 < t+ ∆t
)
P
(
T ∗j0 > t
)
∆t
=
P
(
T ∗jk > t
)
pijλjk(t)
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
+
P
(
T ∗j0 > t
)
(1− pij)λj0(t)
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
=
P
(
T ∗jk > t
)
pijλjk(t) + P
(
T ∗j0 > t
)
(1− pij)λj0(t)
P
(
T ∗jk > t
)
pij + P
(
T ∗j0 > t
)
(1− pij)
=
pijSjk(t)λjk(t) + (1− pij)Sj0(t)λj0(t)
pijSjk(t) + (1− pij)Sj0(t) ,
where pij is the probability of response for patients assigned to Aj as initial treatment ex-
pressed as pij = P (R = 1|Xj = 1). As an example, let J = 2 and K = 2, then the hazards
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under regimes A1B1, A1B2, A2B1 and A2B2 can be written as
λA1B1(t) =
pi1S11(t)λ11(t) + (1− pi1)S10(t)λ10(t)
pi1S11(t) + (1− pi1)S10(t) , (2.2)
λA1B2(t) =
pi1S12(t)λ12(t) + (1− pi1)S10(t)λ10(t)
pi1S12(t) + (1− pi1)S10(t) , (2.3)
λA2B1(t) =
pi2S21(t)λ21(t) + (1− pi2)S20(t)λ20(t)
pi2S21(t) + (1− pi2)S20(t) , (2.4)
and
λA2B2(t) =
pi2S22(t)λ22(t) + (1− pi2)S20(t)λ20(t)
pi2S22(t) + (1− pi2)S20(t) . (2.5)
Corresponding survival functions of four treatment regimes are
SA1B1(t) = pi1S11(t) + (1− pi1)S10(t), (2.6)
SA1B2(t) = pi1S12(t) + (1− pi1)S10(t), (2.7)
SA2B1(t) = pi2S21(t) + (1− pi2)S20(t), (2.8)
and
SA2B2(t) = pi2S22(t) + (1− pi2)S20(t). (2.9)
Thus if one can estimate the probability of response and the survival and hazard functions
λjk(t) and Sjk(t), then the above formulae can be used to estimate the hazard and survival
functions for different regimes. The probability of response for patients assigned to Aj as
initial treatment can be estimated by
pˆij =
∑
XjiRi∑
Xji
.
Nonparametric methods such as Nelson-Aalen (NA), semiparametric methods such as pro-
portional hazards model (PHM), and parametric methods such as accelerated failure time
model (AFTM) can be used to obtain the estimates of six survival functions [S10(t), S20(t),
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S11(t), S12(t), S21(t), S22(t)] and six hazard functions [λ10(t), λ20(t), λ11(t), λ12(t), λ21(t),
λ22(t)] from patients who actually received corresponding treatment sequences (see Sections
2.3.1-2.3.3).
After obtaining the six survival estimates, the survival functions of four treatment
regimes can be easily obtained through SˆA1B1(t) = pˆi1Sˆ11(t) + (1− pˆi1) Sˆ10(t), SˆA1B2(t) =
pˆi1Sˆ12(t) + (1− pˆi1) Sˆ10(t), SˆA2B1(t) = pˆi2Sˆ21(t) + (1− pˆi2) Sˆ20(t), and SˆA2B2(t) = pˆi2Sˆ22(t) +
(1− pˆi2) Sˆ20(t). Similarly, one can obtain the estimates for the hazard functions from equa-
tions (2.2) - (2.5).
2.3.1 Nonparametric Methods
Based on the counting process notations described in Fleming and Harrington [4], the cumu-
lative hazard rate for each subpopulation defined by the survival time T ∗jk, j = 1, 2; k = 0, 1, 2,
can be estimated by the Nelson-Aalen estimator
Λˆjk(t) =
∫ t
0
dNjk(u)
Yjk(u)
,
where Njk(u) is the event process for patients following the treatment path jk at time u
(note that k = 0 indicates that the patient did not make it to the second stage of therapy),
Njk(u) =
n∑
i=1
Njki(u) =
n∑
i=1
I[Ui ≤ u,∆i = 1, Xji = 1, (1−Ri) +RiZki = 1],
and Yjk(u) is the number of individuals at risk at time u given by
Yjk(u) =
n∑
i=1
I[Ui ≥ u,Xji = 1, (1−Ri) +RiZki = 1].
Then the corresponding hazard and survival functions can be estimated by λˆjk(t) =
dΛˆjk(t)
dt
and Sˆjk(t) = exp{−Λˆjk(t)} respectively.
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2.3.2 Semiparametric Methods
Let us assume that there are proportional hazards across different subpopulations defined
by the survival times T ∗jk, j = 1, 2; k = 0, 1, 2, that is, the hazard ratio can be written as
λjk(t)
λj′k′(t)
= eγjkj′k′ ,∀j 6= j′ = 1, 2; k 6= k′ = 0, 1, 2. (2.10)
For simplicity, denote λ0(t) to be the hazard function for patients who were assigned to
initial treatment A1, responded and were assigned to maintenance treatment B1, namely,
λ0(t) = λ11(t). Based on the proportional hazards model, the hazard functions λ10(t),
λ20(t), λ11(t), λ12(t), λ21(t), and λ22(t) are equal to λ0(t)e
γ1011 , λ0(t)e
γ2011 , λ0(t), λ0(t)e
γ1211 ,
λ0(t)e
γ2111 , and λ0(t)e
γ2211 respectively.
The coefficient set under the proportional hazards model is estimated based on the
partial likelihood function [2]. For details, see Therneau and Grambsch [22] Chapter 3.
After fitting the model, the coefficient estimates γˆ = [γˆ1011, γˆ2011, γˆ1211, γˆ2111, γˆ2211]
T and their
estimated variance covariance matrix Σˆ are obtained, as well as the Breslow’s estimator of the
baseline cumulative hazard function Λˆ0(t) and the corresponding baseline hazard function
λˆ0(t) =
dΛˆ0(t)
dt
. Thus, the six estimated survival functions Sˆ10(t), Sˆ20(t), Sˆ11(t), Sˆ12(t),
Sˆ21(t), and Sˆ22(t) can be obtained as Sˆ10(t) = exp(−Λˆ0(t)eγˆ1011), Sˆ20(t) = exp(−Λˆ0(t)eγˆ2011),
Sˆ11(t) = exp(−Λˆ0(t)), Sˆ12(t) = exp(−Λˆ0(t)eγˆ1211), Sˆ21(t) = exp(−Λˆ0(t)eγˆ2111), and Sˆ22(t) =
exp(−Λˆ0(t)eγˆ2211). Similarly, one can obtain the six estimated hazard functions as λˆ10(t) =
λˆ0(t)e
γˆ1011 , λˆ20(t) = λˆ0(t)e
γˆ2011 , λˆ11(t) = λˆ0(t), λˆ12(t) = λˆ0(t)e
γˆ1211 , λˆ21(t) = λˆ0(t)e
γˆ2111 , and
λˆ22(t) = λˆ0(t)e
γˆ2211 .
2.3.3 Parametric Methods
Under specific distributional assumptions about the shape of the survival function, we would
be able to fit accelerated failure time models to different subpopulations defined by the
survival times T ∗jk, j = 1, 2; k = 0, 1, 2 as
lnT ∗jk = µjk + σjkW.
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A variety of distributions can be chosen for the survival time, such as Weibull distribution,
log normal distribution, log logistic distribution, etc. We focus on the estimation for the
Weibull distribution here for demonstration. Under the Weibull distributional assumption,
the hazard and survival functions are given by
Sjk(t) = exp(−λjktαjk),
and
λjk(t) = λjkαt
αjk−1,
where, in many instances, λjk and αjk are reparametrized as λjk = exp(−µjk/σjk) and
αjk = 1/σjk.
The estimates of the parameters µjk and σjk can be obtained through maximum likelihood
method [8]. After fitting the Weibull distribution to the subpopulation, the estimates µˆjk and
σˆjk, their respective estimated variance var(µˆjk) and var(σˆjk), and their estimated covariance
cov(µˆjk, σˆjk) can be obtained. Then the maximum likelihood estimators of parameters λjk
and αjk are given by λˆjk = exp(−µˆjk/σˆjk) and αˆjk = 1/σˆjk. Using the delta method, one
can obtain the estimated variance of λˆjk and αˆjk, and their estimated covariance as follows:
var(λˆjk) = exp
(
−2 µˆjk
σˆjk
)[
var(µˆjk)
σˆ2jk
− 2 µˆjkcov(µˆjk, σˆjk)
σˆ3jk
+
µˆ2jkvar(σˆjk)
σˆ4jk
]
,
var(αˆjk) =
var(σˆjk)
σˆ4jk
,
and
cov(λˆjk, αˆjk) = exp
(
− µˆjk
σˆjk
)[
cov(µˆjk, σˆjk)
σˆ3jk
− µˆjkvar(σˆjk)
σˆ4jk
]
.
Therefore, the hazard and survival functions can be estimated as λˆjk(t) = λˆjkαˆjkt
αˆjk−1 and
Sˆjk(t) = exp(−λˆjktαˆjk). Similarly, their estimated standard errors can be obtained using the
delta method.
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2.3.4 Treatment Regime Comparisons
Comparisons of treatment regimes in terms of their hazards can be carried out by inte-
grating the weighted difference between two cumulative hazard functions [4]. For example,
the Fleming-Harrington linear rank statistics for comparing cumulative hazard functions
ΛA1B1(t) and ΛA2B2(t) is given by
WA1B1/A2B2 =
∫ ∞
0
KA1B1/A2B2(s)
{
dΛˆA1B1(t)− dΛˆA2B2(t)
}
=
∫ ∞
0
KA1B1/A2B2(s)
{
λˆA1B1(s)− λˆA2B2(s)
}
ds,
where the weight of K is chosen according to Feng and Wahed [3] as follows:
KA1B1/A2B2(s) =
{
n11 + n22
n11n22
} 1
2 Y¯11(s)Y¯22(s)
Y¯11(s) + Y¯22(s)
,
where njk, j, k = 1, 2 is the total number of patients following the treatment path jk defined
as njk =
∑n
i=1 I[Xji = 1, (1 − Ri) + RiZki = 1]; Y¯11(s) =
∑n
i=1W11iI(Ui ≥ s); Y¯22(s) =∑n
i=1 W22iI(Ui ≥ s); and Wjki, j, k = 1, 2 is the weight function for the ith patient defined as
Wjki = Xji(1−Ri)+XjiRiZki/piZk . The test statistic WA1B1/A2B2 is asymptotically normally
distributed with mean 0 and some variance σ2WA1B1/A2B2
. We used a bootstrap resampling
method to obtain the estimated variance σˆ2WA1B1/A2B2
.
2.4 SIMULATION STUDY
A Monte-Carlo simulation study was conducted to evaluate the performance of all three
methods described in Section 2.3: Nelson-Aalen (NA) estimator, proportional hazards model
(PHM) and accelerated failure time model (AFTM). A simple two-stage randomization de-
sign was chosen for the simulation study. The indicator for the initial treatment A1 (X1) was
sampled from Bernoulli(0.5) distribution and the intermediate response (R) was drawn from
Bernoulli(0.5) to reflect the response rate in the neuroblastoma dataset. For the responders
indicator for the maintenance treatment B1 (Z1) was generated from Bernoulli(0.5). By
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Table 1: Simulation scenarios
Response Censoring
Responders Nonresponders
True Survival Rates
Rate Percentage t(year) SA1B1(t) SA1B2(t) SA2B1(t) SA2B2(t)
Scenario I 50% 30% Weibull Weibull
1 0.79 0.78 0.77 0.74
3 0.54 0.51 0.55 0.50
6 0.32 0.28 0.38 0.30
Scenario II 50% 30% Log normal Log normal
1 0.80 0.80 0.78 0.76
3 0.48 0.48 0.54 0.48
6 0.27 0.28 0.37 0.30
Scenario III 50% 30% Log logistic Log logistic
1 0.75 0.75 0.76 0.72
3 0.42 0.43 0.52 0.43
6 0.23 0.24 0.38 0.26
Scenario IV 50% 30% Weibull Log normal
1 0.79 0.77 0.77 0.75
3 0.51 0.48 0.54 0.49
6 0.31 0.27 0.38 0.31
Scenario V 50% 30% Log normal Log logistic
1 0.76 0.76 0.76 0.74
3 0.45 0.45 0.51 0.46
6 0.25 0.25 0.36 0.29
equation (2.1), the survival time for the ith patient under a simple two-stage randomization
design can be expressed as
Ti = X1i[(1−Ri)T ∗10i +Ri(Z1iT ∗11i + Z2iT ∗12i)] +X2i[(1−Ri)T ∗20i +Ri(Z1iT ∗21i + Z2iT ∗22i)].
We generated T ∗jk, j = 1, 2; k = 0, 1, 2 from various distributions as described in Table 1.
Under scenario I, the survival times T ∗jk were generated from Weibull distributions, more
explicitly, T ∗jk, j = 1, 2; k = 0, 1, 2 was defined as
T ∗jk =
{− log(u1)
λjk
} 1
αjk
,where u1 ∼ Uniform(0, 1).
Under scenario II, the survival times T ∗jk for each subpopulation followed log normal distri-
butions, thus T ∗jk, j = 1, 2; k = 0, 1, 2 was defined as
T ∗jk = exp{µjk + u2 ∗ σjk},where u2 ∼ Normal(0, 1).
Under scenario III, the survival time T ∗jk for each subpopulation followed a log logistic dis-
tribution, thus T ∗jk, j = 1, 2; k = 0, 1, 2 was defined as
T ∗jk =
{
1/u3 − 1
λjk
} 1
αjk
,where u3 ∼ Uniform(0, 1).
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Under scenario IV, the survival times T ∗jk, j = 1, 2; k = 1, 2 (of responders) followed Weibull
distributions, while the survival times T ∗jk, j = 1, 2; k = 0 (of nonresponders) followed log
normal distributions. Under scenario V, the survival times T ∗jk, j = 1, 2; k = 1, 2 (of re-
sponders) followed log normal distributions, while the survival times T ∗jk, j = 1, 2; k = 0
(of nonresponders) followed log logistic distributions. Censoring time C was drawn from a
uniform distribution, Uniform(25, τ), and τ was selected to achieve a censoring percent-
age of 30% approximately to reflect the censoring rate in the neuroblastoma dataset. For
each scenario, 500 samples of size 400 were generated and a total of seven different models
were fitted to each sample. These models represented the five mixture models presented in
scenarios I to V above plus two others, one used Nelson-Aalen estimator to estimate the
survival for subpopulations and the other used proportional hazards across subgroups (see
Section 2.3). We used a bootstrap resampling method to obtain the variance estimator for
the Fleming-Harrington linear rank statistic.
Simulation results are shown in Tables 2-3. Table 2 and Table 3 display the means of
survival estimates, their estimated standard errors and coverages of probability of 95% confi-
dence interval under scenarios I - V at different time points of 1-year and 3-year respectively.
Since the survival data under scenario I were generated based on the Weibull distribution,
the survival estimates obtained using the Weibull distribution performed very well, as one
would expect, with the coverage probability close to 95% in most of the cases. Some of the
survival estimates obtained using other parametric distributions, e.g. log normal distribu-
tion, were biased, and the coverage probability for one model was as low as 74.6%, which
occurred for SA1B2(t) at 1-year for the log normal models. However, the estimates obtained
using the log logistic distribution were unbiased, and the coverage probabilites were well-
maintained. The coverage probabilities obatined using the PHM were relatively low at early
time points, e.g. at 1-year, perhaps due to the smaller standard error estimates compared to
other models. Furthermore, the survival estimates based on the NA estimator were unbiased
with acceptable coverage probabilities, and the estimated standard errors were relatively
larger compared to the ones we obtained using the other methods. Under scenario II, since
the data were generated based on the log normal distribution, we observed unbiased survival
estimates using the log normal distribution. Other parametric distributions also gave us
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favorable coverage probabilities for the estimates except for the ones we obtained using the
Weibull distribution. Survival estimates obtained using the PHM were noticeably biased at
early time points, but the NA estimators performed very well, coverage probabilities being
well-maintained. Under scenario III, the parametric methods (log normal distribution, log
logistic distribution, and a combination of log normal and log logistic distribution) and NA
estimators performed well, however, the other two parametric methods (Weibull distribution,
and a combination of Weibull and log normal distribution) resulted biased estimates in most
of the cases, and the PHM gave biased estimates at early time points. Under scenario IV, the
data were generated based on a combination of Weibull and log normal distribution, there-
fore, we observed consistent coverage probabilites when the true distributions were fitted to
the data. The estimates obtained using the NA estimator were also unbiased. However, all
the other methods did not perform well, with some of the coverage probilities being smaller
than 95%. Under scenario V, only the estimates calculated based on the Weibull distribution
and the PHM were biased in some of the cases, but all the other methods provided us with
favorable results. Thus, from the results we observed under scenario I - scenario V, it is
clear that PHM does not perform well at early time points on the data generated based on
any parametric distribution. However, NA estimator provides unbiased estimates under all
true models, which is expected as NA estimator is unbiased in large samples. Moreover, the
choice of distribution when fitting the AFTM affects the survival estimates to some extent.
Table 4 presents the rejection rates of the Fleming-Harrington tests based on all seven
methods under scenario I - scenario V for 500 samples of size 400. A total of six null hy-
potheses [H1 : λA1B1(t) = λA1B2(t), H2 : λA1B1(t) = λA2B1(t), H3 : λA1B1(t) = λA2B2(t),
H4 : λA1B2(t) = λA2B1(t), H5 : λA1B2(t) = λA2B2(t), H6 : λA2B1(t) = λA2B2(t)] were tested.
Under scenario I, the rejection rates obtained using all the models were similar to each
other. We also observed similar results under scenario II through scenario V. Under all
the scenarios, the rejection rates obtained using the PHM and NA estimator were observed
to be slightly smaller than the ones obtained using the parametric models in most of the
cases. Thus, we would conclude that Fleming-Harrington test is robust regardless of the
methods used to obtain the hazard and survival estimates. In conclusion, although sur-
vival estimates at specific time points varied somewhat across different methods (NA, PHM,
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Table 2: Survival estimates (EST), standard errors (SE) in parentheses, and coverage probability
of 95% confidence interval (CP) at t = 1 year under scenarios I - V based on samples of size 400
at 50% response rate and 30% censoring percentage. WEI: Weibull distributions, LN: Log normal
distributions, LG: Log logistic distributions, WEILN: Weibull distributions for responders and
log normal distributions for nonresponders, LNLG: Log normal distributions for responders and
log logistic distributions for nonresponders, PHM: Proportional hazards model, NA: Nelson-Aalen
Estimators
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario I
WEI 0.79 (0.028) 95.8 0.78 (0.029) 94.2 0.77 (0.029) 94.6 0.75 (0.030) 94.6
LN 0.76 (0.029) 79.2 0.74 (0.030) 74.6 0.73 (0.030) 79.0 0.71 (0.031) 75.0
LG 0.79 (0.029) 93.6 0.78 (0.030) 92.0 0.76 (0.030) 93.4 0.74 (0.031) 93.0
WEILN 0.77 (0.028) 89.2 0.75 (0.029) 86.0 0.74 (0.029) 85.2 0.72 (0.031) 86.6
LNLG 0.78 (0.029) 90.2 0.76 (0.030) 89.2 0.75 (0.030) 91.0 0.72 (0.031) 88.4
PHM 0.78 (0.026) 96.0 0.76 (0.027) 89.8 0.78 (0.026) 89.8 0.76 (0.028) 91.0
NA 0.79 (0.033) 95.6 0.77 (0.034) 95.2 0.76 (0.034) 94.0 0.74 (0.035) 94.4
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario II
WEI 0.80 (0.027) 97.4 0.80 (0.027) 97.8 0.79 (0.027) 93.8 0.78 (0.028) 93.8
LN 0.80 (0.027) 94.0 0.80 (0.027) 94.4 0.78 (0.027) 93.6 0.76 (0.028) 95.0
LG 0.80 (0.027) 93.6 0.80 (0.027) 94.2 0.79 (0.028) 94.4 0.77 (0.029) 93.8
WEILN 0.79 (0.027) 96.0 0.79 (0.027) 96.4 0.78 (0.027) 95.0 0.76 (0.029) 96.2
LNLG 0.80 (0.027) 92.4 0.80 (0.027) 93.2 0.79 (0.028) 93.2 0.77 (0.029) 94.0
PHM 0.77 (0.026) 88.0 0.77 (0.026) 90.2 0.80 (0.026) 88.8 0.78 (0.027) 90.0
NA 0.79 (0.032) 95.4 0.79 (0.032) 94.6 0.77 (0.032) 94.8 0.76 (0.034) 95.2
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario III
WEI 0.75 (0.029) 96.6 0.76 (0.029) 96.4 0.77 (0.028) 93.2 0.74 (0.031) 93.2
LN 0.74 (0.030) 91.6 0.74 (0.030) 92.0 0.75 (0.029) 93.6 0.71 (0.031) 92.8
LG 0.75 (0.030) 94.8 0.75 (0.030) 94.8 0.76 (0.029) 95.2 0.73 (0.032) 94.2
WEILN 0.74 (0.030) 95.0 0.74 (0.030) 95.2 0.75 (0.028) 95.4 0.72 (0.031) 96.0
LNLG 0.74 (0.031) 94.0 0.75 (0.030) 93.6 0.76 (0.029) 93.4 0.72 (0.032) 92.2
PHM 0.73 (0.029) 90.4 0.73 (0.028) 89.8 0.78 (0.027) 88.0 0.74 (0.029) 88.6
NA 0.74 (0.035) 95.2 0.74 (0.035) 94.6 0.76 (0.033) 95.6 0.72 (0.036) 95.2
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario IV
WEI 0.80 (0.028) 91.6 0.79 (0.028) 92.8 0.79 (0.028) 93.6 0.77 (0.029) 91.8
LN 0.78 (0.028) 89.4 0.77 (0.029) 91.2 0.77 (0.028) 94.2 0.74 (0.030) 93.4
LG 0.80 (0.028) 89.0 0.78 (0.029) 90.4 0.78 (0.029) 95.2 0.76 (0.031) 92.4
WEILN 0.79 (0.028) 93.0 0.78 (0.029) 95.4 0.77 (0.028) 97.0 0.75 (0.029) 95.4
LNLG 0.79 (0.029) 87.8 0.77 (0.030) 91.2 0.77 (0.029) 94.8 0.74 (0.031) 93.8
PHM 0.77 (0.026) 93.2 0.75 (0.027) 90.2 0.79 (0.026) 90.4 0.76 (0.028) 91.6
NA 0.78 (0.033) 93.6 0.77 (0.034) 94.8 0.77 (0.033) 96.2 0.74 (0.035) 95.8
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario V
WEI 0.77 (0.028) 97.2 0.77 (0.028) 97.2 0.77 (0.028) 94.0 0.75 (0.029) 95.2
LN 0.76 (0.028) 94.8 0.76 (0.028) 95.0 0.76 (0.028) 93.4 0.74 (0.030) 94.8
LG 0.77 (0.029) 95.4 0.77 (0.029) 95.6 0.76 (0.029) 94.8 0.74 (0.030) 94.0
WEILN 0.75 (0.029) 96.0 0.75 (0.029) 96.0 0.75 (0.028) 95.2 0.73 (0.030) 95.8
LNLG 0.77 (0.029) 94.8 0.77 (0.029) 95.2 0.76 (0.029) 94.0 0.74 (0.030) 95.0
PHM 0.74 (0.028) 90.2 0.74 (0.028) 92.6 0.78 (0.027) 89.0 0.75 (0.029) 92.6
NA 0.76 (0.033) 94.8 0.76 (0.033) 95.4 0.75 (0.033) 95.6 0.74 (0.035) 95.2
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Table 3: Survival estimates (EST), standard errors (SE) in parentheses, and coverage probability
of 95% confidence interval (CP) at t = 3 year under scenarios I - V based on samples of size 400
at 50% response rate and 30% censoring percentage. WEI: Weibull distributions, LN: Log normal
distributions, LG: Log logistic distributions, WEILN: Weibull distributions for responders and
log normal distributions for nonresponders, LNLG: Log normal distributions for responders and
log logistic distributions for nonresponders, PHM: Proportional hazards model, NA: Nelson-Aalen
Estimators
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario I
WEI 0.54 (0.037) 96.2 0.51 (0.037) 93.4 0.55 (0.037) 93.6 0.50 (0.037) 94.4
LN 0.51 (0.037) 90.8 0.47 (0.037) 86.4 0.53 (0.037) 92.6 0.47 (0.038) 91.0
LG 0.52 (0.039) 94.4 0.49 (0.039) 91.8 0.53 (0.038) 93.6 0.48 (0.039) 93.0
WEILN 0.53 (0.037) 95.8 0.49 (0.037) 93.4 0.54 (0.037) 94.8 0.49 (0.037) 94.2
LNLG 0.51 (0.038) 91.0 0.48 (0.038) 87.2 0.53 (0.037) 92.6 0.47 (0.038) 91.0
PHM 0.53 (0.037) 96.0 0.50 (0.038) 93.2 0.55 (0.038) 94.2 0.50 (0.039) 93.4
NA 0.54 (0.043) 94.2 0.50 (0.043) 93.0 0.54 (0.042) 93.8 0.49 (0.043) 93.6
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario II
WEI 0.53 (0.037) 79.4 0.53 (0.037) 79.8 0.57 (0.036) 87.0 0.52 (0.037) 83.6
LN 0.48 (0.037) 95.4 0.48 (0.037) 93.8 0.54 (0.037) 94.2 0.48 (0.037) 95.2
LG 0.48 (0.039) 95.6 0.48 (0.039) 93.4 0.54 (0.038) 94.0 0.48 (0.039) 95.2
WEILN 0.50 (0.037) 94.2 0.50 (0.037) 94.2 0.55 (0.037) 95.4 0.50 (0.037) 93.6
LNLG 0.48 (0.038) 95.6 0.48 (0.038) 93.0 0.53 (0.037) 93.8 0.48 (0.038) 94.8
PHM 0.47 (0.037) 95.2 0.47 (0.038) 93.0 0.53 (0.038) 96.4 0.48 (0.039) 94.6
NA 0.48 (0.043) 95.2 0.48 (0.043) 94.4 0.53 (0.042) 93.4 0.48 (0.043) 94.6
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario III
WEI 0.46 (0.038) 87.2 0.47 (0.038) 84.4 0.55 (0.037) 87.6 0.47 (0.038) 83.2
LN 0.42 (0.038) 95.6 0.43 (0.038) 95.8 0.52 (0.037) 94.0 0.44 (0.038) 93.0
LG 0.42 (0.039) 94.6 0.43 (0.039) 95.8 0.52 (0.038) 94.6 0.44 (0.039) 93.2
WEILN 0.44 (0.038) 91.8 0.45 (0.038) 92.2 0.54 (0.037) 94.4 0.46 (0.038) 89.2
LNLG 0.42 (0.038) 94.6 0.42 (0.038) 94.6 0.52 (0.037) 93.4 0.43 (0.038) 94.4
PHM 0.41 (0.038) 94.0 0.42 (0.038) 94.2 0.52 (0.039) 93.8 0.44 (0.041) 93.4
NA 0.42 (0.044) 91.0 0.42 (0.043) 92.6 0.52 (0.042) 93.8 0.43 (0.043) 94.2
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario IV
WEI 0.53 (0.037) 89.6 0.50 (0.037) 91.0 0.56 (0.036) 92.2 0.51 (0.037) 91.0
LN 0.49 (0.037) 91.4 0.46 (0.037) 92.0 0.53 (0.037) 94.6 0.47 (0.037) 93.8
LG 0.50 (0.039) 92.6 0.47 (0.039) 93.6 0.53 (0.038) 95.4 0.48 (0.039) 94.4
WEILN 0.51 (0.037) 93.2 0.48 (0.037) 94.6 0.54 (0.037) 95.6 0.49 (0.037) 95.6
LNLG 0.49 (0.038) 89.2 0.45 (0.038) 90.0 0.52 (0.037) 93.8 0.47 (0.038) 91.8
PHM 0.50 (0.038) 93.2 0.47 (0.038) 94.4 0.54 (0.038) 95.6 0.49 (0.039) 96.0
NA 0.51 (0.043) 93.8 0.48 (0.044) 94.6 0.53 (0.042) 95.0 0.49 (0.043) 95.4
A1B1 A1B2 A2B1 A2B2
EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%) EST (SE) CP(%)
Scenario V
WEI 0.49 (0.037) 79.6 0.49 (0.037) 80.6 0.55 (0.037) 86.2 0.50 (0.037) 85.8
LN 0.45 (0.037) 94.8 0.45 (0.037) 95.0 0.52 (0.037) 95.0 0.47 (0.038) 95.0
LG 0.45 (0.039) 95.6 0.45 (0.039) 95.0 0.52 (0.038) 95.4 0.46 (0.039) 93.6
WEILN 0.47 (0.038) 91.0 0.47 (0.037) 90.6 0.53 (0.037) 92.4 0.48 (0.038) 92.2
LNLG 0.45 (0.038) 95.8 0.45 (0.038) 95.4 0.51 (0.037) 95.6 0.46 (0.038) 94.4
PHM 0.43 (0.038) 93.8 0.43 (0.038) 95.2 0.51 (0.039) 93.4 0.46 (0.040) 95.8
NA 0.44 (0.043) 91.6 0.44 (0.043) 94.0 0.51 (0.042) 94.0 0.45 (0.043) 93.6
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Table 4: The rejection rates of Fleming-Harrington tests under scenario I-V based on samples
of size 400 at 50% response rate and 30% censoring percentage. H1 : λA1B1(t) = λA1B2(t), H2 :
λA1B1(t) = λA2B1(t), H3 : λA1B1(t) = λA2B2(t), H4 : λA1B2(t) = λA2B1(t), H5 : λA1B2(t) =
λA2B2(t), H6 : λA2B1(t) = λA2B2(t), WEI: Weibull distributions, LN: Log normal distributions, LG:
Log logistic distributions, WEILN: Weibull distributions for responders and log normal distributions
for nonresponders, LNLG: Log normal distributions for responders and log logistic distributions for
nonresponders, PHM: Proportional hazards model, NA: Nelson-Aalen Estimators
H1 H2 H3 H4 H5 H6
Scenario I
WEI 0.174 0.098 0.090 0.280 0.060 0.298
LN 0.156 0.084 0.090 0.268 0.062 0.290
LG 0.152 0.088 0.084 0.280 0.064 0.286
WEILN 0.164 0.090 0.088 0.284 0.064 0.284
LNLG 0.156 0.092 0.086 0.270 0.060 0.292
PHM 0.152 0.104 0.076 0.294 0.054 0.280
NA 0.174 0.090 0.086 0.246 0.064 0.270
H1 H2 H3 H4 H5 H6
Scenario II
WEI 0.062 0.300 0.066 0.286 0.046 0.284
LN 0.066 0.318 0.066 0.284 0.042 0.282
LG 0.070 0.322 0.062 0.288 0.044 0.286
WEILN 0.062 0.302 0.062 0.282 0.042 0.276
LNLG 0.066 0.308 0.064 0.284 0.042 0.282
PHM 0.060 0.310 0.066 0.282 0.044 0.278
NA 0.060 0.234 0.064 0.232 0.056 0.274
H1 H2 H3 H4 H5 H6
Scenario III
WEI 0.074 0.632 0.088 0.550 0.078 0.542
LN 0.070 0.622 0.080 0.542 0.070 0.538
LG 0.076 0.628 0.092 0.548 0.070 0.548
WEILN 0.076 0.630 0.084 0.540 0.076 0.546
LNLG 0.070 0.624 0.086 0.546 0.070 0.538
PHM 0.060 0.618 0.078 0.546 0.076 0.502
NA 0.074 0.428 0.064 0.412 0.060 0.520
H1 H2 H3 H4 H5 H6
Scenario IV
WEI 0.160 0.172 0.062 0.422 0.080 0.308
LN 0.148 0.152 0.054 0.390 0.066 0.304
LG 0.134 0.152 0.054 0.376 0.070 0.280
WEILN 0.160 0.174 0.062 0.424 0.074 0.308
LNLG 0.152 0.160 0.054 0.382 0.070 0.300
PHM 0.152 0.164 0.038 0.440 0.062 0.284
NA 0.154 0.144 0.048 0.296 0.066 0.254
H1 H2 H3 H4 H5 H6
Scenario V
WEI 0.068 0.384 0.076 0.374 0.072 0.304
LN 0.070 0.382 0.074 0.378 0.074 0.302
LG 0.074 0.398 0.074 0.376 0.070 0.298
WEILN 0.072 0.370 0.080 0.364 0.072 0.304
LNLG 0.070 0.374 0.070 0.374 0.068 0.300
PHM 0.054 0.372 0.068 0.364 0.060 0.290
NA 0.060 0.288 0.068 0.284 0.066 0.294
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AFTM), Fleming-Harrington test of difference in survival/hazard curves between two treat-
ment regimes provided very similar conclusions.
2.5 ANALYSIS OF NEUROBLASTOMA DATASET
A high risk neuroblastoma study was conducted by the Children’s Cancer Group between
1991 and 1996 with the goal of assessing whether a combination of myeloablative chemother-
apy, total-body irradiation, and transplantation of autologous bone marrow purged of cancer
cells (ABMT) improves event-free survival in children with high-risk neuroblastoma com-
pared to intensive non-myeloablative chemotherapy, and to determine whether subsequent
treatment with 13-cis-rectinoic acid (cis-RA) improves event-free survival further compared
to no further therapy [13]. A two-stage randomization design was used for the treatment
assignment. All patients were first treated with induction chemotherapy. Then 379 eligible
patients without progressive diseases participated in the first-stage randomization, with 190
patients assigned to chemotherapy and 189 patients assigned to ABMT. A total of 176 pa-
tients either had progressive diseases or declined further randomization, so only 203 patients
participated in the second stage randomization, with 102 patients assigned to cis-RA and
101 patients assigned to no further therapy. The initial outcome from the neuroblastoma
study was analyzed in Matthay et al. [13]. Matthay et al. [12] reported the long-term study
results. However, both articles separately compared chemotherapy to ABMT, and cis-RA
to no further therapy among those who participated in the second randomization. Such
analyses separated the first and second stage treatments and ignored the information from
those patients who had progressive diseases or declined further randomization, leading to
inefficient use of data.
As described before, there are four possible treatment regimes in this data, namely, CCR,
CNR, ACR, and ANR (see Section 2.1). We first identified the 6 subgroups in the data:
patients who were assigned to chemotherapy as initial treatment and did not respond; pa-
tients who were assigned to chemotherapy as initial treatment, responded and were assigned
to cis-RA as maintenance treatment; patients who were assigned to chemotherapy as initial
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Table 5: AIC values for a total of 18 models fitted to the neuroblastoma dataset
Initial Therapy Response Second-stage Therapy Weibull Log Logistic Log Normal
Chemotherapy No 1109.55 1192.78 1092.47
ABMT No 1173.84 1278.44 1154.31
Chemotherapy Yes cis-RA 618.84 655.84 608.46
Chemotherapy Yes No Further Therapy 619.04 653.88 609.86
ABMT Yes cis-RA 415.74 446.31 409.72
ABMT Yes No Further Therapy 486.77 521.44 479.38
treatment, responded and were assigned to no further therapy; and three other equivalent
subgroups corresponding to those who were assigned to ABMT as initial treatment.
For each subgroup we first computed the survival curve using the NA estimator. Based
on these estimates we obtained the survival curves for the four regimes through the formulae
(2.6)-(2.9) described in Section 2.3. The overall survival curves for these four treatment
regimes (CCR, CNR, ACR, ANR) are shown in Figure 2(a). The survival curves were close
to each other early into the study, but deviated at later times. We then fitted the PHM to
the neuroblastoma data as laid out in Section 2.3 and obtained the estimated survival curves
for the four treatment regimes. The survival curves are depicted in Figure 2(b). The three
survival curves for treatment regimes CCR, CNR, and ANR followed each other, while the
survival curve for ACR was almost always higher compared to other regimes. Finally we
fitted AFTMs to estimate the subgroup-specific survival functions. For each subgroup, we
fitted Weibull, log logistic and log normal distributions and chose the best model with the
lowest Akaike information criterion (AIC). Table 5 presents the AICs for a total of 18 models
involved. It was observed that the AIC was minimum when the log normal distribution was
used as the parametric model for all six subgroups. Figure 2(c) shows the corresponding
overall survival curves for the four treatment regimes. The pattern follows that of the curves
obtained by fitting the PHM. At the late stage of the study, the survival curve for treatment
regime ACR seemed to differ somewhat from the other three survival curves (CCR, CNR,
ANR), while the overall survival curves for treatment regimes CCR, CNR, and ANR followed
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each other closely. The estimated variance for survival estimates were obtained through a
bootstrap resampling method in both the NA estimator and PHM, however, we employed
delta method for the AFTMs. Figure 3 compares all three methods for all four regimes.
The survival curves from the NA estimator, PHM and AFTM were similar to each other,
with small deviations at specific time points. Under the four treatment regimes, the survival
estimates from the AFTM were always slightly larger than the other two during the first five
years of the study, but decreased rapidly afterwards.
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(a) Nelson−Aalen Estimator
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(b) Proportional Hazards Model
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(c) Accelerated Failure Time Model
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Figure 2: Overall survival curves under four treatment regimes in the neuroblastoma study. CCR: “treat with chemotherapy
followed by cis-RA if no progressive disease”, CNR: “treat with chemotherapy followed by no further therapy if no progressive
disease”, ACR: “treat with ABMT followed by cis-RA if no progressive disease”, ANR: “treat with ABMT followed by no
further therapy if no progressive disease”
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Figure 3: Comparisons of three methods for four treatment regimes in the neuroblastoma
study. CCR: “treat with chemotherapy followed by cis-RA if no progressive disease”, CNR:
“treat with chemotherapy followed by no further therapy if no progressive disease”, ACR:
“treat with ABMT followed by cis-RA if no progressive disease”, ANR: “treat with ABMT
followed by no further therapy if no progressive disease” PHM: “Proportional Hazards
Model”, NA: “Nelson-Aalen Estimator”, AFTM: “Accelerated Failure Time Model”
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We performed comparisons of treatment regimes using the NA estimator, PHM and
AFTM respectively. A total of six different hypotheses comparing pairwise treatment regimes
were tested using the Fleming-Harrington two-sample test. The results are shown in Table
6. For simplicity, only first three tests would be described in details. First of all, we tested
if there was a significant difference in the hazards of treatment regimes sharing the same
initial treatment of “chemotherapy.” The null hypothesis can be described as H1 : λCCR(t) =
λCNR(t). The tests resulted in p-values equal to 0.50, 0.90 and 0.96 for the NA estimator,
PHM and AFTM respectively, showing that there was no statistically significant difference
in the hazards of treatment regimes sharing the same initial treatment of “chemotherapy.”
Thus, patients assigned to initial treatment of “chemotherapy” and then assigned to “cis-
RA” upon response had similar survival compared to those assigned to “no further therapy”
upon response to initial treatment of “chemotherapy.”
Secondly, we tested if there was a significant difference in the hazards of treatment
regimes sharing the same maintenance treatment of “cis-RA.” The tests of the null hypothesis
H2 : λCCR(t) = λACR(t) resulted in p-values of 0.22, 0.22 and 0.25 for the NA estimator,
PHM and AFTM respectively. This implied that the null hypothesis would not be rejected
at α = 0.5. Therefore, we would conclude that for patients who were assigned to “cis-RA”
as maintenance treatment upon response, there was no significant difference in the overall
survival between those who were assigned to “chemotherapy” and those who were assigned
to “ABMT” as initial treatment.
The hypothesis that there was no significant difference in the hazards of treatment
regimes with different initial treatments and different maintenance treatments was then
tested using H3 : λCCR(t) = λANR(t). The hazards of CCR and ANR were not statistically
significantly different with the p-values being 0.86, 0.87 and 0.91 for the NA estimator, PHM
and AFTM respectively, implying that there was no difference in the overall survival for pa-
tients who were assigned to “chemotherapy” as initial therapy and “cis-RA” as maintenance
therapy upon response and for those who were assigned to “ABMT” as initial therapy and
“no further therapy” as maintenance therapy upon response. Other pairwise comparisons
were not statistically significant.
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Table 6: Fleming-Harrington test results for the neuroblastoma dataset. CCR: “treat with
chemotherapy followed by cis-RA if no progressive disease”, CNR: “treat with chemotherapy
followed by no further therapy if no progressive disease”, ACR: “treat with ABMT followed
by cis-RA if no progressive disease”, ANR: “treat with ABMT followed by no further therapy
if no progressive disease”, H1 : λCCR(t) = λCNR(t), H2 : λCCR(t) = λACR(t), H3 : λCCR(t) =
λANR(t), H4 : λCNR(t) = λACR(t), H5 : λCNR(t) = λANR(t), H6 : λACR(t) = λANR(t)
Nelson-Aalen Estimator
Test Statistic Standard Error P-value
H1 0.73 1.078 0.50
H2 1.72 1.390 0.22
H3 0.27 1.491 0.86
H4 1.08 1.245 0.39
H5 -0.31 1.337 0.82
H6 -1.37 1.038 0.19
Proportional Hazards Model
Test Statistic Standard Error P-value
H1 0.13 1.049 0.90
H2 1.65 1.354 0.22
H3 0.22 1.371 0.87
H4 1.54 1.260 0.22
H5 0.10 1.272 0.94
H6 -1.37 1.053 0.19
Accelerated Failure Time Model ∗
Test Statistic Standard Error P-value
H1 0.06 1.164 0.96
H2 1.59 1.373 0.25
H3 0.17 1.409 0.91
H4 1.55 1.254 0.22
H5 0.12 1.293 0.93
H6 -1.34 1.068 0.21
∗ Log normal model for each subgroup.
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3.0 COX PROPORTIONAL HAZARDS MODEL FOR COMPARING
DYNAMIC TREATMENT REGIMES WITH TIME DEPENDENT
INTERMEDIATE RESPONSE
3.1 INTRODUCTION
Recently, there has been significant improvement in statistical methods for analyzing sequen-
tially randomized designs [17, 11, 15, 23, 5, 24, 10]. Many of these articles use the idea of
dynamic treatment regimes to analyze the data simultaneously from both stages. Multistage
treatment assignment results in dynamic treatment regimes consisting of initial treatments,
intermediate responses and second stage treatments. For example, one dynamic regime
in the high risk neuroblastoma study could be defined as: “Treat with ABMT followed by
chemotherapy, if the disease remains stable, treat with cis-RA”. Such formulation of dynamic
treatment regimes from multistage treatment assignment allows simultaneous assessment of
both first and second stage treatments. For instance, one could compare the above regime
to a regime that follows ABMT after chemotherapy with no further therapy when disease
remains stable. Murphy et al. [17] provided methodology for estimating mean response to a
dynamic regime under sequential randomization. Lunceford et al. [11] introduced estimators
that account for second randomization and censoring for estimating the survival distribution
and mean restricted survival time for treatment regimes in a two-stage randomized design.
Murphy [15] constructed estimators of optimal dynamic treatment regimes using experimen-
tal or observational longitudinal data. Wahed and Tsiatis [23, 24] presented the most efficient
estimator for the survival distributions utilizing additional information from auxiliary vari-
ables. Guo and Tsiatis [5] proposed a weighted risk set estimator (WRSE) on the basis of
counting process and risk sets [4]. In addition, they also used time-varying measurement
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for the indicator of response and consent. Lokhnygina and Helterbrand [10] implemented
the inverse weighting [19] in the Cox regression methods for the two-stage randomization
design. Furthermore, a consistent estimator for the log hazard in the Cox regression model
and a pseudo-score statistic were also proposed to compare treatment regimes. Thall et al.
[21] used a family of generalized logistic regression models and an approximate Bayesian
method to evaluate multicourse treatment regimes. Murphy and Bingham [16] applied a
new methodology to the identification of potential treatment components and screening out
insignificant ones for developing dynamic treatment regimes.
Cox model provides an effective and efficient way of analyzing survival data in clinical
trials. Lokhnygina and Helterbrand [10] extended the widely used Cox regression method to
two-stage randomization designs. However, it applies only to the comparison of treatment
regimes that share the same second stage therapy. This significantly limits its application
in general settings. Furthermore, it does not take into account the fact that the intermedi-
ate response is a time-varying phenomenon. In this article, we propose a generalized Cox
proportional hazards model that not only applies to comparisons of any combination of any
number of treatment regimes, but also allows the intermediate response to appear as a time-
varying-covariate. We also provide contrasts for comparing treatment regimes and describe
corresponding hypothesis testing process.
This chapter is organized as follows. In Section 3.2, we introduce notation used in this
article. In Section 3.3, we introduce the model framework for estimation and testing. In
Section 3.4, a Monte Carlo simulation study is carried out to examine the performance of
the estimates and the corresponding hypothesis tests. In Section 3.5, we fit the model to
the high risk neuroblastoma dataset to compare overall survival for different neuroblastoma
treatment regimes.
3.2 NOTATION
Consider a two-stage randomization design as depicted in Figure 1, where patients are ran-
domized to J initial treatments, namely, A1, A2, ..., AJ−1, AJ . Patients who responded to
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the initial treatment and provided consent to further participation are subsequently random-
ized to K maintenance treatments, B1, B2, ..., BK−1, BK . Denote by AjBk the treatment
regime “treat with Aj followed by Bk if the patient responds and consents to subsequent
maintenance therapy.” Our goal is to compare regimes AjBk, j = 1, ..., J and k = 1, ..., K
based on the overall survival. The set of observed data from this design can be described as
{Vi, Xji, Ri, RiTRi , RiZki, Ui,∆i},
where Vi denotes the baseline covariates; Xji is the indicator for jth initial treatment, Xji = 1
if the ith patient was assigned to Aj as initial treatment, and Xji = 0 if otherwise; Ri is
the indicator for response and consent, Ri = 1 if the ith patient responded to the initial
treatment and consent to further randomization, and Ri = 0 if otherwise; T
R
i indicates the
time to response and consent; Zki is the indicator for kth maintenance treatment, Zki = 1
if the ith patient was assigned to Bk as maintenance treatment, and Zki = 0 if otherwise
(note that Zki is defined only when Ri = 1); and Ui denotes the observed death (∆i = 1) or
censoring time (∆i = 0). We assume independent right censoring which is customary in the
application of Cox model. Also define Ri(t) = 1 if response and consent have been observed
by time t for the ith patient, and Ri(t) = 0 if otherwise. Note that Ri(t) can be expressed
as Ri(t) = RiI(T
R
i < t) and indicates the time-varying response and consent status.
3.3 THE MODEL
Patients randomized according to a two-stage design (Figure 1) cannot be uniquely attached
to a single regime, since patients not responding to an initial treatment could be considered
following all regimes that share that initial treatment. For example, consider the hypothetical
data from four patients presented in Table 7. Patient P1 is assigned to initial treatment A1,
responded to A1, and then is assigned to maintenance treatment B1, and hence is consistent
with regime A1B1. Patient P2 is also assigned to initial treatment A1 but did not respond
to A1, and thus is consistent with both regimes A1B1 and A1B2. Similarly, patient P3 is
treated consistent to the regime A2B2, and patient P4 to both regimes A2B1 and A2B2. Thus
31
Table 7: Data from four hypothetical patients in a two-stage randomization design.
Patient Initial treatment Respond? Maintenance treatment Regime consistent with
P1 A1 Yes B1 A1B1
P2 A1 No A1B1, A1B2
P3 A2 Yes B2 A2B2
P4 A2 No A2B1, A2B2
standard survival analysis tools such as Kaplan-Meier, log-rank or Cox proportional hazards
models are not directly appropriate. We therefore propose to use the following version of
Cox model
λ(t) = λ0(t) exp
{
J−1∑
j=1
β
(1)
j Xj + β
(2)R(t) +
J−1∑
j=1
β
(3)
j XjR(t) +
K−1∑
k=1
β
(4)
k ZkR(t)
+
J−1∑
j=1
K−1∑
k=1
β
(5)
jk XjZkR(t) + γ
TV
}
≡ λ0(t) exp {G(t)β} , (3.1)
where λ(t) is the general hazard function at time t; λ0(t) denotes the baseline hazard func-
tion (when all the covariates equal to 0); R(t) denotes the time-varying measurement of
response and consent as defined before; β is the vector of coefficients denoted as β =[
β
(1)
1 , . . . , β
(1)
J−1, β
(2), β
(3)
1 , . . . , β
(3)
J−1, β
(4)
1 , . . . , β
(4)
K−1, β
(5)
11 , . . . , β
(5)
(J−1)(K−1), γ
]T
; and G(t) is the
vector of all covariates stacked in the same order as β. Note that in the above model, R(t)
is used as a covariate, which by definition may be affected by the initial treatment and thus
is not exogenous in nature. The goal of this model is neither to draw conclusion about R(t),
nor to draw inferences on the initial treatment. Instead this model aims to assess the effect
of a treatment regime, which is a function of both R(t) and the initial treatment. Therefore,
we do not consider it necessary to elaborate on the endogenous nature of R(t).
For J = K = 2 (i.e. only two treatment options available at each stage), the above
model can be written as
λ(t) = λ0(t) exp
{
β
(1)
1 X1 + β
(2)R(t) + β
(3)
1 X1R(t) + β
(4)
1 Z1R(t) + β
(5)
11 X1Z1R(t) + γ
TV
}
.(3.2)
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Based on model (3.2), the hazard functions for four treatment regimes, namely, A1B1, A1B2,
A2B1, and A2B2 could be written as
λA1B1(t) = λ0(t) exp
{
β
(1)
1 + (β
(2) + β
(3)
1 + β
(4)
1 + β
(5)
11 )R(t) + γ
TV
}
;
λA1B2(t) = λ0(t) exp
{
β
(1)
1 + (β
(2) + β
(3)
1 )R(t) + γ
TV
}
;
λA2B1(t) = λ0(t) exp
{
(β(2) + β
(4)
1 )R(t) + γ
TV
}
;
λA2B2(t) = λ0(t) exp
{
β(2)R(t) + γTV
}
.
A similar model structure for linear regression was proposed in Murphy and Bingham
(2009), however, the model did not include time-varying response structure. Under model
(3.2), comparisons of treatment regimes in terms of their hazards can be interpreted by
the coefficient vector β =
[
β
(1)
1 , β
(2), β
(3)
1 , β
(4)
1 , β
(5)
11 , γ
]T
. When comparing treatment regimes
sharing the same initial therapy, e.g., comparing A1B1 to A1B2 and comparing A2B1 to
A2B2, the null hypothesis H1 : λA1B1(t) = λA1B2(t) is equivalent to H1 : β
(4)
1 + β
(5)
11 = 0, and
the null hypothesis H2 : λA2B1(t) = λA2B2(t) is equivalent to H2 : β
(4)
1 = 0. When comparing
treatment regimes sharing the same maintenance therapy, e.g., comparing A1B1 to A2B1
and comparing A1B2 to A2B2, the null hypothesis H3 : λA1B1(t) = λA2B1(t) is equivalent to
H3 : β
(1)
1 = 0; β
(3)
1 + β
(5)
11 = 0, and the null hypothesis H4 : λA1B2(t) = λA2B2(t) is equivalent
to H4 : β
(1)
1 = β
(3)
1 = 0. Furthermore, for comparing all four treatment regimes in a simple
two-stage randomization design, the null hypothesis H5 : λA1B1(t) = λA1B2(t) = λA2B1(t) =
λA2B2(t) can be interpreted as H5 : β
(1)
1 = β
(3)
1 = β
(4)
1 = β
(5)
11 = 0.
In all of the above cases, no single relative risk can be used to estimate the relative effect
of one regime vs. the other, since a time-varying measurement of response and consent is
involved in their hazard functions. For example, the hazard ratio at time t for the regime
A1B1 and A1B2 is given by λA1B1(t)/λA1B2(t) = exp
{(
β
(4)
1 + β
(5)
11
)
R(t)
}
, which is not a
constant. It depends on whether the patient responded by time t or not. Thus if two patients
received the same initial therapy A1 and did not respond by time t, then their hazards are
identical, which is what one would expect. However, if these two patients had responded by
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time t, then their hazard ratio would be exp
(
β
(4)
1 + β
(5)
11
)
. Model (3.1) can also be extended
to compare any combination of any number of treatment regimes (see discussion).
Coefficients of Cox model with time-dependent covariates are usually estimated using
maximum likelihood method through partial likelihood [2, 22]. The log partial likelihood
function based on model (3.1) is given by
l(β) =
n∑
i=1
∫ ∞
0
{
Yi(t)Gi(t)β − log
(∑
p
Yp(t) exp [Gp(t)β]
)}
dNi(t),
where Ni(t) = I(Ui ≤ t,∆i = 1) and Yi(t) = I(Ui ≥ t). The coefficients are obtained by
solving the score equations defined below
U(β) =
n∑
i=1
∫ ∞
0
{Gi(t)− g(β, s)} dNi(s) = 0,
where
g(β, s) =
∑
Yp(s) exp [Gp(s)β]Gp(s)∑
Yp(s) exp [Gp(s)β]
.
It is well-known that the estimated coefficients βˆ are asymptotically normally distributed
with mean β and variance covariance matrix Σ, which is usually estimated by I−1(βˆ), where
I−1(βˆ) =

n∑
i=1
∫ ∞
0
∑
Yp(s) exp
[
Gp(s)βˆ
] [
Gp(s)− g(βˆ, s)
]′ [
Gp(s)− g(βˆ, s)
]
∑
Yp(s) exp
[
Gp(s)βˆ
] dNi(s)

−1
.
For details, see Therneau and Grambsch [22] Section 3. The estimation is done using the
Newton-Raphson algorithm in statistical packages such as SAS [20] and R [18]. Both the
PHREG procedure in SAS and the coxph function in the “survival” package of R can easily
fit this Cox proportional hazards model.
After fitting model (3.2), the coefficient estimates βˆ and their estimated variance covari-
ance matrix Σˆ are obtained. Then the null hypotheses described above can be tested using
Wald chi-square tests. For example, the null hypothesis H3 : λA1B1(t) = λA2B1(t) could be
tested using a Wald chi-square test statistic with two degrees of freedom. The test statistic
can be written as
χ22 = (Aβˆ)
T
(AT ΣˆA)−1(Aβˆ),
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where
A =
 1 0 0 0 0
0 0 1 0 1
 .
This test statistics then is compared to the critical values from a χ22 distribution.
3.4 SIMULATION STUDY
The performance of the generalized Cox proportional hazards model was evaluated by con-
ducting a Monte Carlo simulation study. For simplicity, and to maintain similarity with
the neuroblastoma dataset, a simple two-stage randomization design allowing two treatment
options at each stage was chosen. Overall sample size n was varied between 200 and 800
with step-wise increments of 200. Indicator for initial treatment A1 (X1) was sampled from
Bernoulli(0.5) distribution. V was chosen to be a one-dimensional auxiliary covariate gen-
erated from normal distribution with mean 1 and standard deviation 0.5. We generated the
“response time” TR from Exponential(α). We followed Leemis et al. (1990) to generate
survival time from Cox model with time-dependent covariates. Let u be a single observation
drawn from a uniform distribution, Uniform(0,1), and λ be the exponential baseline function,
namely, λ0(t) = λ. Then the response status for the ith patient was defined by
Ri =
0 if 0 < −log(1− ui)/λ < T
R
i exp (β
(1)
1 X1i + γVi),
1 if −log(1− ui)/λ ≥ TRi exp (β(1)1 X1i + γVi).
Indicator for maintenance treatment B1 (Z1) was sampled from Bernoulli(0.5) distribution,
defined only under the condition that R = 1. Since our Cox proportional hazards model
includes both time-change covariate and other fixed covariates, piecewise exponentially dis-
tributed death times were generated for nonresponders (R = 0) and responders (R = 1) [9].
The survival time for the ith patient was defined as
Ti =

−log(1−ui)
λ exp (β
(1)
1 X1i+γVi)
if Ri = 0,
−log(1−ui)−TRi λ exp (β(1)1 X1i+γVi)
λ exp (β
(1)
1 X1i+β
(2)+β
(3)
1 X1i+β
(4)
1 Z1i+β
(5)
11 X1iZ1i+γVi)
+ TRi if Ri = 1.
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Censoring time C was drawn from a Uniform(0, θ) distribution. These set-up ensured that
survival time T follows a Cox proportional hazards model with time dependent measurement
of response and consent R(t) as defined in Section 3.2:
λ(t) = λ0(t) exp
{
β
(1)
1 X1 + β
(2)R(t) + β
(3)
1 X1R(t) + β
(4)
1 Z1R(t) + β
(5)
11 X1Z1R(t) + γV
}
.
Simulation parameters λ, α and θ were selected to achieve permutations of 40%, 50%, 60%
response rate and 50%, 30% censoring percentage approximately, whereas other param-
eters (β
(1)
1 , β
(2), β
(3)
1 , β
(4)
1 , β
(5)
11 , γ) were chosen to reflect the status of different hypotheses
in the true population. For simplicity, we planned to test only the following three null
hypotheses: H1 : λA1B1(t) = λA1B2(t), H3 : λA1B1(t) = λA2B1(t), and H5 : λA1B1(t) =
λA1B2(t) = λA2B1(t) = λA2B2(t). These hypotheses are equivalent to H1 : β
(4)
1 + β
(5)
11 = 0,
H3 : β
(1)
1 = 0; β
(3)
1 + β
(5)
11 = 0, and H5 : β
(1)
1 = β
(3)
1 = β
(4)
1 = β
(5)
11 = 0 respectively.
Therefore, in the first simulation scenario, the set of coefficients {β(1)1 , β(2), β(3)1 , β(4)1 , β(5)11 , γ}
was chosen to be {−0.5,−0.8, 0.5, 1,−1,−0.5} to study the performance of Wald chi-square
tests for H1 : λA1B1(t) = λA1B2(t) (note that β
(4)
1 + β
(5)
11 = 0, which indicates that in
the true population H1 is true); in the second scenario, the set of coefficients was cho-
sen to be {0, 0.1,−0.8, 2, 0.8,−0.5} to study the performance of Wald chi-square tests for
H3 : λA1B1(t) = λA2B1(t) (note that β
(1)
1 = 0; β
(3)
1 + β
(5)
11 = 0); in the third scenario,
the set of coefficients was chosen to be {0, 0.8, 0, 0, 0,−0.5} to study the performance of
Wald chi-square tests for H5 : λA1B1(t) = λA1B2(t) = λA2B1(t) = λA2B2(t) (note that
β
(1)
1 = β
(3)
1 = β
(4)
1 = β
(5)
11 = 0). For each scenario, 2,000 samples of size n were drawn
and model (3.2) described in Section 3.3 was fitted to each sample using coxph function in
R.
Simulation results are shown in Tables 8-11. Table 8 shows the estimated coefficients,
standard errors (SE), Monte-Carlo standard errors (MCSE) and coverage probabilities (CP)
of 95% confidence intervals under scenario I. The estimated coefficients were approximately
unbiased. The largest absolute bias (0.05) occurred for β(2) under a smaller sample size of
400, a relatively larger censoring percentage of 50% and a smaller response rate of 40%. In
most cases absolute biases were less than 0.03. The standard errors were close to the Monte-
Carlo standard errors, demonstrating that the estimated standard errors were consistent.
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The coverage probabilities of 95% confindence intervals were within the range of 93.9% to
96.1%, attaining the nominal level of 95% in most of the cases. The results were similar for
both 40% and 60% response rates. However, as expected, both absolute biases and standard
errors became smaller with increasing sample size and decreasing censoring percentage. In
Tables 9 and 10, we presented the simulation results under scenarios II and III respectively.
Similar to the results of scenario I, under scenario II, estimators performed well, with small
absolute biases. Coverage probabilities were in the interval of 94.2% and 96.3%. We observed
even better performance under scenario III, with absolute biases even smaller (less than 0.02).
The coverage probabilities under scenario III were between 94.2% and 95.9%.
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Table 8: Simulation results under scenario I. True values of coefficients are β
(1)
1 = −0.5, β(2) =
−0.8, β(3)1 = 0.5, β(4)1 = 1.0, β(5)11 = −1.0, γ = −0.5. Est = mean of estimated coefficients,
Bias = | Estimate - True |, SE = mean of estimated standard errors, MCSE = Monte-Carlo
standard deviation of the estimators and CP = coverage probability of 95% CI.
n = 400
Response 50% censoring 30% censoring
Rate Coef Est Bias SE MCSE CP(%) Est Bias SE MCSE CP(%)
40% β
(1)
1 -0.51 0.01 0.182 0.184 95.3 -0.51 0.01 0.153 0.154 95.2
β(2) -0.85 0.05 0.333 0.335 96.1 -0.83 0.03 0.266 0.271 94.8
β
(3)
1 0.53 0.03 0.445 0.456 94.7 0.52 0.02 0.343 0.360 93.9
β
(4)
1 1.04 0.04 0.366 0.372 95.2 1.03 0.03 0.298 0.300 94.9
β
(5)
11 -1.04 0.04 0.537 0.544 95.5 -1.03 0.03 0.416 0.418 95.3
γ -0.51 0.01 0.149 0.152 95.0 -0.51 0.01 0.124 0.127 94.4
60% β1 -0.51 0.01 0.249 0.258 94.9 -0.51 0.01 0.188 0.191 95.0
β(2) -0.82 0.02 0.299 0.303 95.0 -0.82 0.02 0.244 0.250 94.5
β
(3)
1 0.52 0.02 0.391 0.401 95.2 0.51 0.01 0.309 0.317 94.5
β
(4)
1 1.02 0.02 0.270 0.271 95.7 1.02 0.02 0.237 0.238 95.3
β
(5)
11 -1.02 0.02 0.399 0.401 95.0 -1.03 0.03 0.335 0.338 95.5
γ -0.51 0.01 0.153 0.155 94.9 -0.51 0.01 0.126 0.128 94.8
n = 600
Response 50% censoring 30% censoring
Rate Coef Est Bias SE MCSE CP(%) Est Bias SE MCSE CP(%)
40% β
(1)
1 -0.50 0.00 0.148 0.147 94.9 -0.50 0.00 0.125 0.124 95.1
β(2) -0.81 0.01 0.267 0.266 95.5 -0.80 0.00 0.214 0.212 95.5
β
(3)
1 0.50 0.00 0.357 0.364 94.7 0.49 0.01 0.277 0.280 95.4
β
(4)
1 1.01 0.01 0.293 0.296 95.6 1.00 0.00 0.240 0.238 95.7
β
(5)
11 -1.01 0.01 0.430 0.432 95.3 -1.00 0.00 0.336 0.339 95.2
γ -0.50 0.01 0.121 0.121 94.8 -0.51 0.01 0.101 0.103 94.5
60% β
(1)
1 -0.50 0.00 0.202 0.199 95.6 -0.50 0.00 0.153 0.151 95.1
β(2) -0.81 0.01 0.242 0.242 95.0 -0.80 0.00 0.198 0.198 94.8
β
(3)
1 0.50 0.00 0.315 0.314 95.2 0.50 0.00 0.251 0.246 95.6
β
(4)
1 1.01 0.01 0.218 0.221 95.3 1.00 0.00 0.192 0.196 94.7
β
(5)
11 -1.01 0.01 0.322 0.325 95.4 -1.01 0.01 0.272 0.272 95.3
γ -0.51 0.01 0.124 0.125 94.8 -0.51 0.01 0.102 0.104 94.4
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Table 9: Simulation results under scenario II. True values of coefficients are β
(1)
1 = 0, β
(2) =
0.1, β
(3)
1 = −0.8, β(4)1 = 2.0, β(5)11 = 0.8, γ = −0.5. Est = mean of estimated coefficients, Bias
= | Estimate - True |, SE = mean of estimated standard errors, MCSE = Monte-Carlo
standard deviation of the estimators and CP = coverage probability of 95% CI.
n = 400
Response 50% censoring 30% censoring
Rate Coef Est Bias SE MCSE CP(%) Est Bias SE MCSE CP(%)
40% β
(1)
1 -0.00 0.00 0.199 0.204 94.5 -0.00 0.00 0.158 0.159 95.0
β(2) 0.07 0.03 0.316 0.316 96.2 0.08 0.02 0.240 0.245 94.7
β
(3)
1 -0.83 0.03 0.512 0.523 95.5 -0.82 0.02 0.360 0.370 94.5
β
(4)
1 2.04 0.04 0.327 0.333 95.9 2.03 0.03 0.266 0.266 95.5
β
(5)
11 0.83 0.03 0.533 0.541 95.4 0.82 0.02 0.399 0.387 96.3
γ -0.50 0.00 0.148 0.151 94.8 -0.50 0.00 0.123 0.125 94.8
60% β
(1)
1 -0.01 0.01 0.259 0.267 95.1 -0.00 0.00 0.208 0.211 95.1
β(2) 0.07 0.03 0.316 0.327 94.8 0.09 0.01 0.242 0.248 94.6
β
(3)
1 -0.82 0.02 0.490 0.514 95.0 -0.81 0.01 0.343 0.341 95.7
β
(4)
1 2.04 0.04 0.284 0.288 95.4 2.03 0.03 0.225 0.232 94.6
β
(5)
11 0.83 0.03 0.462 0.476 95.1 0.80 0.00 0.331 0.327 95.0
γ -0.50 0.00 0.150 0.150 95.0 -0.50 0.00 0.125 0.127 94.5
n = 600
Response 50% censoring 30% censoring
Rate Coef Est Bias SE MCSE CP(%) Est Bias SE MCSE CP(%)
40% β
(1)
1 0.00 0.00 0.162 0.162 94.8 0.00 0.00 0.129 0.129 94.9
β(2) 0.09 0.01 0.254 0.256 95.4 0.10 0.00 0.195 0.192 95.4
β
(3)
1 -0.83 0.03 0.409 0.415 95.4 -0.82 0.02 0.290 0.299 94.2
β
(4)
1 2.02 0.02 0.263 0.262 95.3 2.01 0.01 0.215 0.213 95.6
β
(5)
11 0.84 0.04 0.425 0.432 94.7 0.82 0.02 0.322 0.325 95.3
γ -0.51 0.01 0.120 0.122 94.8 -0.50 0.00 0.100 0.102 95.0
60% β
(1)
1 0.00 0.00 0.211 0.212 94.7 0.00 0.00 0.169 0.166 95.5
β(2) 0.10 0.00 0.255 0.255 95.5 0.10 0.00 0.197 0.196 95.6
β
(3)
1 -0.83 0.03 0.392 0.400 95.1 -0.81 0.01 0.278 0.283 94.8
β
(4)
1 2.01 0.01 0.228 0.233 94.7 2.01 0.01 0.182 0.184 94.9
β
(5)
11 0.83 0.03 0.369 0.375 95.1 0.81 0.01 0.268 0.269 95.2
γ -0.51 0.01 0.121 0.124 94.6 -0.51 0.01 0.101 0.103 95.0
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Table 10: Simulation results under scenario III. True values of coefficients are β
(1)
1 = 0, β
(2) =
0.8, β
(3)
1 = 0, β
(4)
1 = 0, β
(5)
11 = 0, γ = −0.5. Est = mean of estimated coefficients, Bias = |
Estimate - True |, SE = mean of estimated standard errors, MCSE = Monte-Carlo standard
deviation of the estimators and CP = coverage probability of 95% CI.
n = 400
Response 50% censoring 30% censoring
Rate Coef Est Bias SE MCSE CP(%) Est Bias SE MCSE CP(%)
40% β
(1)
1 -0.01 0.01 0.199 0.203 94.3 -0.01 0.01 0.162 0.163 95.3
β(2) 0.79 0.01 0.265 0.267 95.1 0.79 0.01 0.219 0.224 94.3
β
(3)
1 0.02 0.02 0.362 0.368 94.4 0.01 0.01 0.300 0.310 94.2
β
(4)
1 0.01 0.01 0.303 0.304 95.6 0.00 0.00 0.253 0.253 95.3
β
(5)
11 -0.02 0.02 0.429 0.432 95.1 -0.01 0.01 0.357 0.355 95.5
γ -0.51 0.01 0.148 0.149 95.3 -0.51 0.01 0.123 0.126 94.4
60% β
(1)
1 -0.01 0.01 0.254 0.262 95.1 -0.00 0.00 0.204 0.206 95.0
β(2) 0.79 0.01 0.270 0.281 94.7 0.80 0.00 0.218 0.224 94.8
β
(3)
1 0.02 0.02 0.361 0.376 94.2 0.01 0.01 0.291 0.298 94.5
β
(4)
1 0.01 0.01 0.256 0.259 94.5 0.00 0.00 0.207 0.209 94.7
β
(5)
11 -0.01 0.01 0.363 0.365 95.2 -0.01 0.01 0.293 0.292 95.9
γ -0.51 0.01 0.149 0.151 95.1 -0.50 0.00 0.122 0.126 94.2
n = 600
Response 50% censoring 30% censoring
Rate Coef Est Bias SE MCSE CP(%) Est Bias SE MCSE CP(%)
40% β
(1)
1 0.00 0.00 0.161 0.162 94.7 0.00 0.00 0.132 0.131 95.7
β(2) 0.81 0.01 0.214 0.214 95.3 0.80 0.00 0.178 0.176 95.8
β
(3)
1 -0.01 0.01 0.293 0.296 95.6 0.00 0.00 0.244 0.247 94.9
β
(4)
1 -0.01 0.01 0.244 0.244 95.6 -0.00 0.00 0.205 0.205 95.2
β
(5)
11 0.01 0.01 0.346 0.347 95.2 0.00 0.00 0.289 0.292 94.8
γ -0.51 0.01 0.120 0.120 94.8 -0.51 0.01 0.100 0.102 94.9
60% β
(1)
1 0.00 0.00 0.206 0.207 95.2 0.00 0.00 0.166 0.163 95.4
β(2) 0.81 0.01 0.219 0.217 95.8 0.81 0.01 0.177 0.177 95.7
β
(3)
1 -0.01 0.01 0.293 0.296 94.8 -0.01 0.01 0.236 0.237 94.9
β
(4)
1 -0.00 0.00 0.207 0.208 95.6 -0.00 0.00 0.168 0.172 95.0
β
(5)
11 -0.00 0.00 0.293 0.296 94.8 0.00 0.00 0.238 0.242 94.7
γ -0.51 0.01 0.121 0.123 94.4 -0.51 0.01 0.099 0.102 95.0
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Table 11 gives the Type I errors or powers of Wald chi-square tests under different
scenarios for samples of sizes 400 and 600. Scenario I was generated based on the null
hypothesis H1 : λA1B1(t) = λA1B2(t), so one would expect that the rejection rates for null
hypothesis H1 would be close to the nominal level of 0.05. The simulation results show
rejection rates for testing H1 to be near 0.05. The powers for the two other null hypotheses
H3 and H5 under scenario I were maintained above 0.96, with a small increase resulting
from an increase in the sample size. Scenario II was generated based on the null hypothesis
H3 : λA1B1(t) = λA2B1(t). Similar to the rejection rates for null hypothesis H1, type I error
was well-maintained (∼ 0.05) for this scenario, and the powers for the null hypotheses H1
and H5 were all equal to 1.00. Scenario III was generated based on the null hypothesis
H5 : λA1B1(t) = λA1B2(t) = λA2B1(t) = λA2B2(t). Because null hypothesis H5 implies null
hypotheses H1 and H3, the rejection rates for all three null hypotheses under scenario III
were close to 0.05. These results imply that comparative hypothesis testing can be performed
maintaining adequate type I errors from the proposed model.
3.5 ANALYSIS OF NEUROBLASTOMA DATASET
In the neuroblastoma study, all patients were treated with induction chemotherapy first.
Then 379 eligible patients without progressive disease participated in the first stage ran-
domization, with 190 patients assigned to chemotherapy and 189 patients assigned to a
combination of myeloablative chemotherapy, total-body irradiation, and transplantation of
autologous bone marrow purged of cancer cells (ABMT). A total of 176 patients either had
progressive disease or declined further randomization, so only 203 patients participated in the
second stage randomization, with 102 patients assigned to cis-RA and 101 patients assigned
to no further therapy. Thus, there are four possible treatment regimes in the neuroblastoma
study: (i) treat with chemotherapy followed by cis-RA if no progressive disease (CCR); (ii)
treat with chemotherapy followed by no cis-RA if no progressive disease (CNR); (iii) treat
with ABMT followed by cis-RA if no progressive disease (ACR); (iv) treat with ABMT
followed by no cis-RA if no progressive disease (ANR).
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Table 11: Wald chi-square test results under scenarios I, II and III based on samples of sizes
400 and 600. H1 : λA1B1(t) = λA1B2(t), H3 : λA1B1(t) = λA2B1(t), and H5 : λA1B1(t) =
λA1B2(t) = λA2B1(t) = λA2B2(t)
n = 400
50% censoring 30% censoring
Type I error/Power Type I error/Power
Scenario Response Rate H1 H3 H5 H1 H3 H5
I 40% 0.049 0.968 0.968 0.047 0.996 0.996
50% 0.050 0.972 0.989 0.054 0.998 0.999
60% 0.052 0.987 0.994 0.057 0.999 0.999
II 40% 1.000 0.049 1.000 1.000 0.049 1.000
50% 1.000 0.059 1.000 1.000 0.052 1.000
60% 1.000 0.058 1.000 1.000 0.049 1.000
III 40% 0.055 0.046 0.045 0.052 0.052 0.055
50% 0.053 0.054 0.055 0.048 0.050 0.048
60% 0.051 0.055 0.055 0.046 0.048 0.055
n = 600
50% censoring 30% censoring
Type I error/Power Type I error/Power
Scenario Response Rate H1 H3 H5 H1 H3 H5
I 40% 0.051 0.998 1.000 0.059 1.000 1.000
50% 0.041 1.000 1.000 0.051 1.000 1.000
60% 0.050 1.000 1.000 0.052 1.000 1.000
II 40% 1.000 0.053 1.000 1.000 0.047 1.000
50% 1.000 0.050 1.000 1.000 0.045 1.000
60% 1.000 0.047 1.000 1.000 0.048 1.000
III 40% 0.055 0.051 0.051 0.053 0.052 0.053
50% 0.054 0.044 0.049 0.052 0.054 0.052
60% 0.055 0.046 0.048 0.048 0.048 0.043
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Figure 4: Overall survival curves under four treatment regimes in the neuroblastoma study.
CCR: “treat with chemotherapy followed by cis-RA if no progressive disease”, CNR: “treat
with chemotherapy followed by no cis-RA if no progressive disease”, ACR: “treat with ABMT
followed by cis-RA if no progressive disease”, ANR: “treat with ABMT followed by no cis-RA
if no progressive disease”
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Table 12: Wald chi-square test results for the neuroblastoma dataset. CCR: “treat with
chemotherapy followed by cis-RA if no progressive disease”, CNR: “treat with chemotherapy
followed by no cis-RA if no progressive disease”, ACR: “treat with ABMT followed by cis-RA
if no progressive disease”, ANR: “treat with ABMT followed by no cis-RA if no progressive
disease”
df Test Statistic P-value
H1 : λCCR(t) = λCNR(t) 1 0.06 0.81
H2 : λACR(t) = λANR(t) 1 2.20 0.14
H3 : λCCR(t) = λACR(t) 2 3.92 0.14
H4 : λCNR(t) = λANR(t) 2 0.47 0.79
H5 : λCCR(t) = λCNR(t) = λACR(t) = λANR(t) 4 5.45 0.24
We first used the weighted risk set estimator (WRSE) [5] to estimate the overall survival
curves. Overall survival curves under these four treatment regimes are presented in Figure
4. Apparently survival curves are close to each other during the first three years. They
somewhat deviate from each other at later times but do not meet the criteria for statistical
significance in adjusted analysis described as follows. We fitted the Cox proportional hazards
model (3.2) to this data, including auxiliary covariates age, Evans stage, MYCN oncogene
amplification (MYCN), histology, ferritin and initial response to induction chemotherapy.
These covariates were identified as the potential prognostic factors diagnosed in Matthay
et al. [12]. The covariate Evans stage was grouped as “stage 4,” “stages other than stage
4” and “unknown.” Histology was grouped as “favorable,” “unfavorable” and “unknown.”
Ferritin was grouped as “normal,” “elevated” and “unknown.” Initial response to induc-
tion chemotherapy contained 8 levels: CR(complete response), VGPR(very good partial re-
sponse), PR(partial response), SD(stable disease), MR(mixed response), PD(progressive dis-
ease), NR(no response) and missing. We categorized it into “CR/VGPR,” “PR,” “SD/MR,”
“PD” and “unknown” as was done by clinicians, see Matthay et al. [12].
Several different hypotheses comparing the treatment regimes were tested. The results
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are summarized in Table 12. To test if there was a significant difference in the hazards of
treatment regimes sharing the same initial treatment “chemotherapy,” we set up the hypothe-
sis H1 : λCCR(t) = λCNR(t). The p-value from the Wald test was equal to 0.81, implying that
there was no statistically significant difference in the hazards of treatment regimes sharing
the same initial treatment “chemotherapy.” In other words, for patients who were assigned
to initial treatment “chemotherapy,” there was no difference in the overall survival whether
they continued with maintenance treatment “cis-RA” or “no further therapy.” The hypoth-
esis that there was no significant difference in the hazards of treatment regimes sharing the
same initial treatment “ABMT” was then tested using H2 : λACR(t) = λANR(t). The p-value
for this test was 0.14, which would mean that for patients who were assigned to “ABMT”
as initial treatment, there was no difference in the overall survival whether they continued
with maintenance treatment “cis-RA” or “no further therapy.” The hypotheses tests for
difference in the hazards of treatment regimes sharing the same maintenance treatment “cis-
RA” or “no further therapy,” namely, H3 : λCCR(t) = λACR(t) and H4 : λCNR(t) = λANR(t),
resulted in p-values 0.14 and 0.79 respectively, demonstrating that for patients who were
assigned to “cis-RA” as maintenance treatment, regardless of which initial therapy they
were assigned to, there was no difference in their overall survival, and the same was true
for patients who were assigned to “no further therapy” as maintenance treatment. Sub-
sequently, the difference in the hazards of four treatment regimes was examined through
H5 : λCCR(t) = λCNR(t) = λACR(t) = λANR(t). The hazards of four treatment regimes were
not statistically significantly different with p-value being 0.24. Thus, there was no difference
in the overall survival irrespective of which initial treatment patients were assigned to and
which maintenance treatment they were subsequently assigned to.
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4.0 CONCLUSIONS
In Chapter 2, we demonstrated the use of the Nelson-Aalen estimator, proportional hazards
model and accelerated failure time model for estimating the effects of treatment regimes from
two-stage randomization designs. We also demonstrated how to compare different regimes
in terms of their hazards using the Fleming-Harrington two-sample tests.
The simulation study showed that survival estimates could differ when a model other
than the true model was fitted. Thus, the survival estimates were affected somewhat by
the choice of distributions when fitting the accelerated failure time model. The proportional
hazards model provided slightly biased estimates at earlier time points, however, the survival
estimates obtained using the NA estimator were unbiased. The performance of the Nelson-
Aalen estimator, proportional hazards model and accelerated failure time model were also
evaluated at other response rates, censoring percentages, and for various sample sizes. We
observed similar results using the proportional hazards model and accelerated failure time
model at different censoring percentages, however, the Nelson-Aalen estimator provided bi-
ased estimates in small samples. When the response rate is as small as 40% and the overall
sample size is relatively small such as 400, all the three methods show some bias in the
survival estimates due to the small sample size in each subgroup.
Furthermore, the simulation study also showed that the rejection rates obtained us-
ing all the methods were similar to each other under all scenarios, demonstrating that the
Fleming-Harrington two-sample test was robust regardless of the methods for estimating
the survival quantities. When we utilized Fleming-Harrington two-sample tests to compare
different treatment regimes in terms of their hazards, six pairs of null hypotheses were tested
separately. In this circumstance, how small a p-value is considered significant needs further
discussion. As we know, many statistical techniques have been developed for protecting
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the Type I errors in multiple comparisons, e.g. Bonferroni correction, Holm’s sequential
rejection procedure, etc. Similar techniques could possibly be adopted here. However, we
decided to pursue this in a separate research study. The methodology proposed here resem-
bles the pattern-mixture models in the missing data literature ([14] Chapter 16), where the
parameter estimates are estimated for each missing data pattern and then overall estimate
is calculated as a weighted average of the pattern-specific estimates. If we look closely at
equations (2.6)-(2.9), we see that for each strategy, the survival function is calculated as the
weighted average of the two sequence(pattern)-specific survival estimates.
In Chapter 3, we proposed a generalized Cox proportional hazards model for comparing
dynamic treatment regimes from sequentially randomized designs. In the simulation study
we examined the performance of the proposed model fitting and showed that it performed
well for moderate to large samples of sizes 200 to 800. Even in a large percentage of 50%
censoring, the estimates were approximately unbiased and the coverage probabilites were
consistent with the nominal level. The model was used to analyze the neuroblastoma dataset.
Our analysis showed that neuroblastoma treatment regimes were similar in terms of overall
survival, even though the survival probability at specific time points may be significantly
different in analysis separated by stages [12].
The methodology proposed can be used to analyze survival data from sequentially as-
signed treatment trials or studies, regardless of the number of stages of treatment or number
of available treatment options at each stage. Although two-stage randomization designs were
used for demonstration throughout the article, the model also applies to multistage random-
ization designs with more than two stages. For example, under a three-stage randomization
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design, the Cox model can be written as
λ(t) = λ0(t) exp
{
J−1∑
j=1
β
(1)
j Xj + β
(2)R1(t) +
J−1∑
j=1
β
(3)
j XjR1(t) +
K−1∑
k=1
β
(4)
k ZkR1(t)
+
J−1∑
j=1
K−1∑
k=1
β
(5)
jk XjZkR1(t) + β
(6)R2(t) +
J−1∑
j=1
β
(7)
j XjR2(t) +
K−1∑
k=1
β
(8)
k ZkR2(t)
+
J−1∑
j=1
K−1∑
k=1
β
(9)
jk XjZkR2(t) +
P−1∑
p=1
β(10)p YpR2(t) +
J−1∑
j=1
P−1∑
p=1
β
(11)
jp XjYpR2(t)
+
K−1∑
k=1
P−1∑
p=1
β
(12)
kp ZkYpR2(t) +
J−1∑
j=1
K−1∑
k=1
P−1∑
p=1
β
(13)
jkp XjZkYpR2(t) + γ
TV
}
,
where R1(t) indicates the time-varying response and consent status after first stage treat-
ment; R2(t) denotes the time-varying measurement of response and consent after second
stage treatment; and Yp is the indicator for pth treatment at third stage. As the number of
stages involved in a design increases, it becomes increasingly complex to explicitly write down
the Cox model, as the number of parameters increases rapidly. However, the implementation
using standard software packages is straightforward.
The inclusion of R(t) as a covariate in the model demands further discussion. At first
glance, one may hesitate to use R(t) (an endogenous covariate) in the model with the fear
of blurring the direct effect of the initial treatment with its indirect effect through response.
But the goal of such analysis is to assess the regime effect, which by definition puts the direct
and indirect effects in one bin. The inclusion of R(t) in the model should merely be seen as
a tool to facilitate the comparisons of different treatment regimes.
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